Non-Hodgkin Lymphoma

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation · 2026 · PMID 42420469

Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transp…

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.

The British journal of dermatology · 2025 · PMID 40795052

In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lympho…

[China lymphoma diagnosis and treatment guideline (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 41876194

Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of C…

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics · 2026 · PMID 41785936

Extranodal natural killer/T-cell lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. These evidence-based recommendations for natural killer/T-cell lymphoma by the American Radium Society were developed by a multidisciplinary panel of medical and radiation oncologists to propose treatment approaches. This guideline was based on a literature review with a consensus methodology to rate the appropriateness of treatment recommendations for each natural killer/T-cell lymphoma clinical presentation. Six va…

Large B-cell lymphoma: The LYSA pragmatic guidelines.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41352004

The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances i…

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41031482

This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists…

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026 · PMID 42323047

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next…

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · PMID 41067277

The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest t…

[The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025 · PMID 41339040

Marginal zone lymphoma (MZL) is an indolent B-cell lymphoma arising from marginal zone B cells within lymphoid follicles, accounting for approximately 5%-15% of non-Hodgkin lymphomas. MZL is characterized by diagnostic challenges and diverse treatment options, making it a challenging subtype in clinical practice. In recent years, with the rapid progress in lymphoma research, the understanding of MZL has improved significantly worldwide. To further standardize the diagnosis and treatment of MZL in China, the Chinese…

Radiotherapy for haematological malignancies: Current best practices and advancements.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025 · PMID 41106036

Haematological malignancies include a broad spectrum of diseases. The substantial progress made in systemic treatment over the last 20years is reshaping the role of radiotherapy. Recent technological progress in imaging and radiotherapy has led to significant refinements in targets definition, sparing of organ at risk to reduce toxicity, thus ensuring that radiotherapy remains the cornerstone for several indications. We present the recommendations of the Société française de radiothérapie oncologique for radiothera…

A practical approach to panel design, validation, and interpretation for the evaluation of T-cell neoplasms by flow cytometry.

Cytometry. Part B, Clinical cytometry · 2025 · PMID 41122063

The diagnosis of T-cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This "Best Practice" manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T-cell neoplasms. We outline the utility of key antigens in the screening and classification of T-cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical str…

Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025 · PMID 40924120

The growing use of reduced-dose radiotherapy in patients with primary cutaneous lymphoma is a promising development. Nevertheless, the absence of controlled clinical trials to ascertain standardized doses for each specific type constitutes a significant impediment to the advancement of this field. This expert opinion strongly advocates for advancements in radiation oncology practice that address the unique complexities of primary cutaneous lymphoma. By refining our methodologies, we can optimize patient care and ou…

Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.

Bone marrow transplantation · 2025 · PMID 41034407

This manuscript provides expert recommendations on the role of allogeneic hematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides (MF) and Sezary Syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and hematologists. …

SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 41129029

Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological subtype of non-Hodgkin lymphoma and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hematopathologist is recommended to establish the diagnosis. Twenty years following its introduction, the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment. No modification of this scheme (increas…

Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025.

The Journal of dermatology · 2025 · PMID 41204060

Since the publication of the Japanese guidelines for the management of cutaneous lymphomas in 2020, the WHO classification of hematolymphoid neoplasms has been updated, and a number of novel systemic drugs for cutaneous T-cell lymphoma have been approved in Japan. In 2025, we revised the Japanese guidelines for the management of cutaneous lymphomas in consideration of recent advances in our understanding of the pathophysiology and classification of cutaneous lymphomas, together with the update in treatment strategi…

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352

INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …

The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.

British journal of haematology · 2024 · PMID 38247115

Adiposity and cancer: systematic review and meta-analysis.

Nature metabolism · 2026 · PMID 42297908

Obesity is a major health challenge. Here we show that body mass index is positively associated with risk of 19 cancers and inversely associated with 3, based on a systematic review and meta-analysis of prospective studies of 25 cancer types. We searched PubMed, EMBASE and Scopus through to 23 April 2025, identifying 226 articles comprising 1.5 million incident cancers. We identified positive associations for leukaemia, non-Hodgkin lymphoma, bladder cancer and glioma, not previously identified by major consensus re…

Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.

Journal of comparative effectiveness research · 2026 · PMID 42359923

Aim: Several CAR-T cell therapies have received regulatory approval from both the US FDA and the EMA for the treatment of large B-cell lymphoma. However, direct comparative trials between CAR-T cell therapies are lacking, mainly due to different clinical development timelines and availabilities as well as substantial resource requirements and difficulties in recruiting sufficiently large and homogeneous cohorts from a highly pre-treated patient population. Consequently, indirect treatment comparisons (ITCs) play a …

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma.

Blood cancer journal · 2025 · PMID 41461632

There is currently no clear consensus on the standard of care for relapsed or refractory follicular lymphoma (FL) beyond third-line therapy, where both anti-CD19 CAR-T-cell therapy (CAR-T) and CD3×CD20 bispecific antibodies (BsAbs) have demonstrated efficacy. This study aimed to examine their efficacy and toxicity profiles. Relevant studies published between January 2010 and June 2025 were identified through major databases. Of 3960 records screened, 12 studies met the inclusion criteria-7 involving CAR-T and 5 inv…

Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials.

BMJ open · 2026 · PMID 41651511

INTRODUCTION: Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that primarily affects the skin and can mimic inflammatory dermatoses. Unlike many skin diseases, CTCL can lead to disabling symptoms, and advanced CTCL can even be fatal. Early studies investigating health-related quality of life (HRQOL) in patients with mycosis fungoides (MF) and Sézary syndrome (SS), common subtypes of CTCL, demonstrated significant impairment across numerous domains. The aim of this current study is to develop a …

Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.

Current oncology (Toronto, Ont.) · 2026 · PMID 42645356

Relapsed and/or refractory follicular lymphoma (R/R FL) remains a therapeutic challenge due to its chronic relapsing course and increasingly complex treatment landscape. Novel therapies, including immunomodulatory combinations, bispecific antibodies (BsAbs), Bruton tyrosine kinase inhibitors, and chimeric antigen receptor (CAR) T-cell therapies, have expanded treatment options and increased the complexity of treatment selection and sequencing. The Canadian Hematology Consensus Group (CHCG) convened a national panel…

Current status of hematopoietic cell transplantation in patients with peripheral T-cell lymphoma including adult T-cell leukemia-lymphoma.

International journal of hematology · 2026 · PMID 41283963

Peripheral T-cell lymphomas (PTCLs) are biologically diverse and clinically aggressive, and are difficult to control long-term with conventional immunochemotherapy. Hematopoietic cell transplantation (HCT) is a key treatment option. Autologous HCT (auto-HCT) as first-line consolidation has shown durable progression-free survival in phase 2 studies and in the auto-HCT arm of the randomized AATT trial (intent-to-treat PFS 30-49%), although its routine use after complete metabolic response remains controversial. A pha…

Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.

European journal of haematology · 2026 · PMID 41360116

Identifying patients eligible for front-line clinical trials with diffuse large B-cell lymphoma (DLBCL) has been challenging, primarily due to increasingly stringent inclusion criteria and the limitations of the International Prognostic Indices in identifying patients who are unlikely to achieve long-term remission after standard treatment. We aimed to assess the impact of using improved eligibility criteria established through a US-based Delphi-method survey to identify real-world DLBCL patients eligible for clini…

Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.

Blood · 2026 · PMID 41490516

Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month land…

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674

The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …

Prostate lymphoma uncovered during urological encounters: Diagnostic challenges and clinical outcomes in a case series with systematic review of the literature.

Urologic oncology · 2026 · PMID 42686439

INTRODUCTION: Prostatic lymphoma is a rare malignancy that can clinically resemble benign prostatic hyperplasia (BPH) or adenocarcinoma, often delaying diagnosis. Primary prostatic lymphoma (PPL) comprises <0.1% of prostate tumors and non-Hodgkin lymphomas, whereas secondary involvement occurs more commonly in systemic disease. METHODS: A retrospective review was conducted at the University of Miami Health System (2015-2024). All prostate specimens demonstrating lymphoma or related hematologic malignancies were ide…

Pulmonary amyloidosis, gastric MALT lymphoma, and multiple sclerosis in a patient with Sjögren's disease: a case report and review of the literature.

Rheumatology international · 2026 · PMID 42640321

Sjögren's disease (SjD) is a systemic autoimmune disorder associated with lymphocytic gland infiltration and an increased risk of B-cell lymphomas, particularly mucosa-associated lymphoid tissue (MALT) lymphoma. Neurological involvement may mimic multiple sclerosis (MS), while true coexistence, especially with amyloidosis, is exceptionally rare. We performed a systematic review and present a representative clinical case. A registered systematic literature review (PROSPERO CRD4201332325) was conducted according to P…

Antibody-drug conjugate development in lymphoma: a systematic clinical trial landscape analysis.

Frontiers in immunology · 2026 · PMID 42620849

INTRODUCTION: Antibody-drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate development trends, evidence maturity, molecular architecture, combination strategies, inactive development, and safety reporting. METHODS: We searched Trialtrove for Phase I-IV interventional trials evaluating at least one ADC in lymphoma, with actual or anticipated star…

Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.

Haematologica · 2025 · PMID 40207715

The multi-center randomized phase III NHL-004 study compared etoposide, dexamethasone and pegaspargase (ESA) versus the methotrexate, etoposide, dexamethasone and pegaspargase (MESA) regimen, combined with sandwiched radiotherapy, in newly diagnosed early-stage nasal natural killer / T-cell lymphoma (NKTCL). Here we report the long-term outcomes (median follow-up, 64 months) and biomarker analysis. A total of 256 eligible patients aged 14-70 years were randomly assigned (1:1) to the ESA or the MESA arm. The 5-year …

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology · 2026 · PMID 42240061

One quarter of patients with diffuse large B-cell lymphoma (DLBCL) who achieve a complete response following front-line therapy will eventually experience disease relapse. Existing prognostic models use baseline factors to predict outcomes from the start of initial therapy and are not intended for use following completion of treatment. We developed a conditional event-free survival (cEFS) tool that predicts a patient's risk of lymphoma recurrence after completing front-line therapy taking into consideration baselin…

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 41825137

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)-containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel…

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances · 2026 · PMID 41979332

Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 c…

Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study.

Journal of neuro-oncology · 2026 · PMID 42667447

BACKGROUND: Primary Large-B-Cell Lymphoma of the CNS (PCNS-LBCL) is a rare, aggressive tumor often sensitive to corticosteroid therapy (CST). This multicenter study investigated the spectrum of radiological responses to routine CST and evaluated its impact on patient prognosis. METHODS: The researchers utilized a prospective cohort of 18 patients for volumetric MRI analysis and a combined prospective-retrospective cohort of 31 patients for 2D tumor analysis. Patients received CST post-biopsy, with follow-up MRIs pe…

An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 42584691

OBJECTIVES: To develop an individualized nomogram for predicting disease progression risk in systemic anaplastic large cell lymphoma (sALCL). METHODS: Independent predictors of progression-free survival (PFS) were identified using Cox regression in a multicenter retrospective cohort of 109 sALCL patients (2010-2022). These were incorporated into a three-factor nomogram, evaluated via bootstrapped internal validation (1000 resamples), ROC analysis, C-index, decision curve analysis (DCA), and clinical impact curve (C…

Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.

Annals of medicine · 2026 · PMID 42482660

BACKGROUND: CD5-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype with poor outcomes. Following the approval of Pola-R-CHP in China, this study aimed to evaluate its efficacy as initial therapy for this high-risk population. METHODS: We conducted a multicenter, retrospective study of previously untreated CD5-positive DLBCL patients who received Pola-R-CHP as first-line therapy between April 2023 and February 2025. Treatment response was assessed by PET/CT after 3 cycles and at the end of treat…

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41645921

BACKGROUND: The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: 'SKIN disease profiling by an Exploratory, pRospective, biomarker study …

Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.

European journal of nuclear medicine and molecular imaging · 2026 · PMID 42223630

PURPOSE: The clinical use of CD3-CD20-directed bispecific antibodies (BsAbs) has significantly improved outcomes of patients with relapsed/refractory LBCL. However, up to 50% of patients relapse. This study evaluated the prognostic value of longitudinal FDG-PET parameters. METHODS: 58 patients with baseline PET and 45 (78%) with first PET after BsAb initiation were included. Standard PET metrics and Deauville score (DS) were recorded, with percent changes at follow-up defined as ΔPET parameters. Prognostic impact o…

Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index in Patients With Lymphoma.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026 · PMID 42002076

OBJECTIVES: To further evaluate the psychometric properties of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18), including estimates of meaningful within-patient change thresholds, to support its ability to reliably and validly measure clinical- and patient-relevant outcomes in diverse research settings. METHODS: Data from a longitudinal multicenter clinical trial in patients with indolent B cell lymphoma and a single-institution observational …

Immunohistochemical Expression of p63 and GATA3 in Lymphomas of the Urinary Bladder: A Clinicopathologic Study of a Potential Diagnostic Pitfall.

International journal of surgical pathology · 2026 · PMID 41985039

Urinary bladder lymphomas are rare and may mimic urothelial carcinoma by morphology or unexpected expression of putative "urothelial" markers such as p63/ GATA3, the latter of which has not been thoroughly explored. Herein, we evaluate the clinicopathologic features of bladder lymphomas and assess the incidence of p63/GATA3 expression. A multi-institutional review identified 28 bladder lymphomas. Slides were re-reviewed for lymphoma subtype, growth pattern, urothelial colonization, and concurrent urothelial carcino…

Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

Blood cancer discovery · 2026 · PMID 42446920

UNLABELLED: Disease recurrence is the main cause of treatment failure after CD19-directed chimeric antigen receptor (CAR) T cells, often due to CD19 antigen loss, stability, and/or coverage. To overcome single-antigen escape, we evaluated a trispecific CAR targeting CD19, CD20, and CD22 with an OX40 costimulatory domain. Preclinical studies demonstrated potent, antigen-specific cytotoxicity in in vitro and in vivo lymphoma models. We then conducted a first-in-human phase I trial in patients with relapsed/refractory…

Metabolic Tumor Area: A Clinically Practical Prognostic Marker for Improved Risk Stratification in IPI Non-High-Risk DLBCL.

Hematological oncology · 2026 · PMID 42633636

Metabolic tumor volume (TMTV) is a core 18F-FDG PET/CT prognostic marker for diffuse large B-cell lymphoma (DLBCL), but its complex measurement and limited standardization restrict clinical utility. Metabolic tumor area (MTA) features simple operation and good reproducibility, holding potential as a practical alternative to TMTV. This retrospective study aimed to validate MTA's substitutability and explore its prognostic value in DLBCL risk stratification. A total of 295 newly diagnosed DLBCL patients were enrolled…

Primary cutaneous lymphomas in children: a single-center retrospective analysis and narrative review of the literature.

Italian journal of dermatology and venereology · 2026 · PMID 42166117

BACKGROUND: Primary cutaneous lymphomas (PCLs) are uncommon in children, with mycosis fungoides (MF), lymphomatoid papulosis (LyP), and primary cutaneous small/medium CD4+ T-cell lymphoproliferative disorder (PCSM-TCLPD) representing the most frequent entities. Due to their rarity, available data derive mainly from case reports and small series, and diagnostic delays are frequent. This study aimed to describe the clinical, histopathological, and therapeutic features of pediatric PCLs in a single Italian referral ce…

Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades.

Journal of cancer survivorship : research and practice · 2025 · PMID 37938431

PURPOSE: The impact of changes in therapy for childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) on the prevalence of physical performance limitations and participation restrictions among survivors is unknown. We aimed to describe the prevalence of reduced function among ALL and NHL survivors by treatment era. METHODS: Participants included survivors of childhood ALL and NHL, and a cohort of their siblings, participating in the Childhood Cancer Survivor Study (CCSS). Physical function was m…

Survival and prognostic features of early-stage diffuse large B-cell lymphoma in older adults.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 41922932

BACKGROUND: Early-stage diffuse large B-cell lymphoma (ESDLBCL) in older adults is understudied, and existing prognostic tools such as the stage-adjusted International Prognostic Index (Sa-IPI) may not adequately account for comorbidity and age-related vulnerability. This study evaluated long-term outcomes and developed a simplified prognostic index for patients aged ≥ 60 years with ESDLBCL. METHODS: We retrospectively analyzed adults aged ≥ 60 years with stage I-II DLBCL treated at King Hussein Cancer Center betwe…

Hematologic Malignancies Among Adults in Southeast Asia: Incidence, Mortality, and Regional Contexts.

JCO global oncology · 2025 · PMID 41397191

PURPOSE: Southeast Asia (SEA), home to over 690 million people across 11 countries-Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor-Leste, and Vietnam-features diverse socioeconomic contexts and cancer care landscapes. We report and interpret incidence and mortality statistics for hematologic malignancies (HMs) in SEA. METHODS: We analyzed 2022 Global Cancer Observatory data from the International Agency for Research on Cancer to report age-standardized incidence …

Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response.

Haematologica · 2025 · PMID 40371889

Accurate detection of patients at high risk of treatment failure following first-line immunochemotherapy in diffuse large B-cell lymphoma (DLBCL) is of paramount importance as patients might benefit from early treatment escalation. Recently, we introduced the International Metabolic Prognostic Index (IMPI) based on metabolic tumor volume (MTV), age and stage that outperformed the International Prognostic Index. However, radiomic features such as the maximum distance between the largest lesion and another lesion (Dm…

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.

Leukemia · 2026 · PMID 42414604

The clinical course of Mantle Cell Lymphoma (MCL) varies between individual patients. Early detection of risk is crucial to assign MCL patients to novel treatment strategies. Most of the established biomarkers of outcome require specifically trained pathologists or molecular analysis. Here we introduce MAIPI (MCL Artificial Intelligence Prognostic Index), a deep learning algorithm trained only on Hematoxylin and Eosin (H&E) images of diagnostic biopsies of n = 428 MCL patients from clinical trials to assess prognos…

Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma.

La Radiologia medica · 2026 · PMID 42322517

OBJECTIVES: To evaluate whether baseline splenic ^18F-FDG PET uptake and CT-derived spleen volume predict early progression (≤ 36 months) and progression-free survival (PFS) in diffuse large B cell lymphoma (DLBCL), and whether they interact. MATERIALS AND METHODS: Retrospective cohort of adults with newly diagnosed DLBCL undergoing baseline ^18F-FDG PET/CT and CT. Splenic PET positivity was defined visually (uptake exceeding hepatic background); spleen volume was measured semi-automatically. Early progression/rela…

[China lymphoma diagnosis and treatment guideline (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 41876194

Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of C…

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation · 2026 · PMID 42420469

Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transp…

Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis.

BMC cancer · 2026 · PMID 42332608

BACKGROUND: The survival rate for hematologic malignancies is steadily improving. With the encouraging trend and the aging of these survivors, there is an ever-increasing responsibility for identifying adverse cardiovascular outcomes associated with carcinogenesis and/or anti-cancer therapies across the span of their lives. However, prospective studies have yielded inconsistent results. METHODS: We performed a meta-analysis to summarize the evidence regarding the association between leukemia, Hodgkin lymphoma (HL),…

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics · 2026 · PMID 41785936

Extranodal natural killer/T-cell lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. These evidence-based recommendations for natural killer/T-cell lymphoma by the American Radium Society were developed by a multidisciplinary panel of medical and radiation oncologists to propose treatment approaches. This guideline was based on a literature review with a consensus methodology to rate the appropriateness of treatment recommendations for each natural killer/T-cell lymphoma clinical presentation. Six va…

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026 · PMID 42323047

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next…

Association between interleukin-10 (IL-10) genetic polymorphisms and non-hodgkin lymphoma: a systematic review and meta-analysis.

Leukemia & lymphoma · 2026 · PMID 42335190

Non-Hodgkin lymphoma (NHL) has been associated with IL-10 single-nucleotide polymorphisms (SNPs), although findings remain inconsistent. This meta-analysis aims to investigate the association between key IL-10 SNPs (rs1800871, rs1800872, rs1800890, and rs1800896) with NHL. A systematic search of multiple databases was conducted to get relevant articles. The study included 53,864 cases and 60,448 controls from 41 studies. Pooled ORs with 95% CIs were calculated for each SNP, along with a heterogeneity test and publi…

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.

Blood cancer journal · 2026 · PMID 42362499

Pola-R-CHP regimen is the new standard of care for untreated diffuse large B-cell lymphoma (DLBCL) patients, following the POLARIX trial. This study evaluates whether clinical trial (RCT) efficacy and safety are reproducible in real-world evidence (RWE) settings. This systematic review and meta-analysis compared outcomes between RCTs and RWE studies. Primary endpoints were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Meta-regression explored heterogeneity using age, Inter…

Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed/refractory indolent B-cell non-Hodgkin's lymphomas.

Journal of translational medicine · 2025 · PMID 41456045

BACKGROUND: Indolent B-cell non-Hodgkin’s lymphomas (B-NHLs), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), typically demonstrate slow progression but frequently follow a relapsing-remitting course with conventional therapies. Chimeric antigen receptor T-cell (CAR-T) and bi-specific antibodies (BsAbs) therapies have revolutionized treatment for relapsed/refractory (R/R) B-NHLs. However comparative data on the efficacy of CAR-T therapy versus BsAbs in indolent B-NHLs remain limited. This meta-…

Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.

Transplantation and cellular therapy · 2026 · PMID 41525947

In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.

The Lancet. Haematology · 2026 · PMID 42069410

BACKGROUND: The treatment landscape for relapsed or refractory diffuse large B-cell lymphoma has changed profoundly with the introduction of novel drug classes, some approved solely on the basis of single-arm early-phase trials. We aimed to evaluate antitumour activity and safety outcomes across drug classes in early-phase trials in relapsed or refractory diffuse large B-cell lymphoma since 2000. METHODS: We did a systematic review and meta-analysis of phase 1-2 trials. We searched PubMed, Embase.com, Web of Scienc…

Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42177127

INTRODUCTION: Survival outcomes of patients with mantle cell lymphoma (MCL) have substantially improved. In the setting of extended overall survival (OS), progression-free survival (PFS) is typically used as a primary endpoint in MCL clinical trials rather than OS to limit trial duration and cost. However, no prior analysis has assessed whether PFS can reliably predict OS. The aim of this study is to perform a systematic evaluation of PFS as a surrogate endpoint for OS in phase III MCL clinical trials. MATERIALS AN…

Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with peripheral T-cell lymphoma: a meta-analysis.

Annals of medicine · 2025 · PMID 39928126

BACKGROUND: Previous studies have explored whether soluble programmed cell death ligand-1 (sPD-L1) can be used to predict the prognosis of patients with peripheral T-cell lymphoma (PTCL); however, no consistent results have been obtained. Consequently, we conducted the present meta-analysis to identify the precise significance of sPD-L1 in predicting the prognosis of PTCL. METHODS: We searched PubMed, Embase, Web of Science, and the Cochrane Library until July 31, 2024. The value of sPD-L1 in predicting PTCL progno…

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.

Frontiers in immunology · 2026 · PMID 42495620

This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neuroto…

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology · 2026 · PMID 42313425

IMPORTANCE: T-cell-engaging bispecific antibodies (BsAbs) are increasingly used in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). As these agents transition into earlier courses of therapy and broader clinical use, understanding their safety profile is critical. While second primary malignant neoplasms (SPMs) represent a key long-term safety signal, small sample sizes, single-arm trials, short follow-up, and heterogeneous reporting have limited reliable estimation of their frequency. OBJECTIVE: To est…

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology · 2026 · PMID 42383996

Relapsed/refractory follicular lymphoma (R/R FL) remains a clinically challenging condition, with progressively declining benefit across consecutive lines of therapy. While anti-Cluster of Differentiation 20 (CD20) antibodies remain the therapeutic backbone, the optimal targeted or immune-based partner remains undefined. A systematic review and network meta-analysis (NMA) of 5 phase III and 1 phase II trials (2500 patients) evaluated seven anti-CD20-based combination strategies. Primary end-points were overall surv…

Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.

Acta neurologica Belgica · 2026 · PMID 41212511

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…

CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.

La Clinica terapeutica · 2026 · PMID 42340791

BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…

Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.

PeerJ · 2026 · PMID 42428526

BACKGROUND AND OBJECTIVES: Large B-cell lymphoma (LBCL) is a common and aggressive non-Hodgkin lymphoma (NHL) characterized by abnormal proliferation of mature B lymphocytes, with a 10-year prevalence of up to 45 cases per 100,000 individuals in European populations and a continuing upward trend. Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) are the two most established chimeric antigen receptor T-cell (CAR-T) therapy products for LBCL, yet a systematic comparison of their efficacy and safety in…

Efficacy of zanubrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.

Critical reviews in oncology/hematology · 2026 · PMID 41786108

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, and previous studies have indicated the potential of zanubrutinib in the treatment of DLBCL. This meta-analysis aims to evaluate the efficacy of zanubrutinib in DLBCL patients and further explore potential differences in treatment effects across diverse patient subgroups. METHODS: A systematic literature search was conducted using two major databases (PubMed and Embase) and four key conference websites to e…

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation · 2026 · PMID 42332219

Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. This systematic review evaluates the safety, efficacy, and feasibility of bendamustine-based LD in patients undergoing CAR-T therapy for hematologic malignancies. A comprehensive literature …

Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.

Blood advances · 2026 · PMID 41587420

Follicular lymphoma with progression of disease within 24 months (POD24) is associated with poor prognosis and represents clinical challenges. Therefore, we performed a systematic review and pooled analysis of patients with POD24. Twenty-one trials involving 1242 participants were included, assessing the overall response rate (ORR), complete response (CR), duration of response, and progression-free survival. In some trials, we compared pooled response rates between POD24 and non-POD24 populations with the same trea…

Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.

Annals of hematology · 2026 · PMID 42118323

Patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who experience disease progression following anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy face poor prognoses and limited therapeutic options. Bispecific antibodies (BsAbs) have emerged as a promising salvage strategy. This meta-analysis was conducted to evaluate the efficacy and safety of CD3×CD20 BsAbs in R/R LBCL patients after CAR-T failure. Clinical studies published between 2021 and 2025 were systematically reviewed, and a r…

Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.

Cancer · 2026 · PMID 42487493

BACKGROUND: Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts. METHODS: The authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus…

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352

INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.

Transplantation and cellular therapy · 2024 · PMID 38972511

Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over the past decade, but the disease continues to be considered incurable. Hematopoietic cell transplantation (HCT) is potentially curative in some cases. Recently, the emergence of chimeric antigen receptor T-cell therapy (CAR-T) for patients with relapsed/refractory (R/R) FL has yielded impressive response rat…

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.

Blood advances · 2025 · PMID 40590871

CD3xCD20 bispecific antibody (BsAb) therapy and CD19-directed chimeric antigen receptor T-cell therapy (CAR T) are novel immunotherapies that have shown impressive efficacy in B-cell lymphomas, but also come with significant morbidity and mortality, including infections. This meta-analysis compares rates of infections between commercially approved CAR T and BsAb therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL). We conducted a systematic review for prospective trials assessing commercially approved CAR T…

Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population.

Leukemia · 2025 · PMID 39707004

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and the most common form of non-Hodgkin lymphoma (NHL) that occurs worldwide. To discover risk factors and pathogenesis of DLBCL, we performed the largest GWAS of DLBCL to date in samples of East Asian ancestry, consisting of 2,888 patients with DLBCL and 12,458 controls. The meta-analysis identified three novel loci, rs2233434 on 6p21.1 (OR = 1.26, P = 1.17 × 10-8), rs11066015 on 12q24.12 (OR = 1.24, P = 6.57 × 10-9) and rs6032662 on 20q13.12 (OR = …

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.

Haematologica · 2024 · PMID 38497149

Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) carries a dismal prognosis and most clinical guidelines recommend CNS prophylaxis to patients deemed at high risk of CNS relapse. However, results from observational studies investigating the effect of CNS prophylaxis have yielded conflicting results. The aims of this study were to evaluate: (i) whether addition of prophylactic intravenous high-dose methotrexate (HD-MTX) reduces the risk of CNS relapse in high-risk DLBCL pat…

Benzene exposure and non-Hodgkin lymphoma: a systematic review and meta-analysis of human studies.

The Lancet. Planetary health · 2021 · PMID 34450064

BACKGROUND: Non-Hodgkin lymphoma comprises a heterogeneous group of cancers with unresolved aetiology, although risk factors include environmental exposures to toxic chemicals. Although the ubiquitous pollutant benzene is an established leukemogen, its potential to cause non-Hodgkin lymphoma has been widely debated. We aimed to examine the potential link between benzene exposure and risk of non-Hodgkin lymphoma in humans by evaluating a wide array of cohort and case-control studies using electronic systematic revie…

Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry.

Blood reviews · 2021 · PMID 33187810

The clinical relevance of flow cytometry (FC)-based bone marrow involvement (BMI) in B cell non-Hodgkin lymphoma (B-NHL) is not well established. We conducted a systematic review of MEDLINE regarding the use of FC to establish BMI in B-NHL to determine the prevalence of BMI by FC, to understand the interrelation between FC and bone marrow biopsy (BMB), and to explore the prognostic impact of BMI by FC. Relevant exclusion criteria included publication before 2010. Eleven publications (of 18 screened) were included, …

Association of diabetes mellitus with non-Hodgkin lymphoma risk: a meta-analysis of cohort studies.

Hematology (Amsterdam, Netherlands) · 2019 · PMID 31262228

Background: Diabetes mellitus (DM) is considered to be a risk factor in the prognosis of many types of cancer, but the effect of DM on the risk of non-Hodgkin lymphoma (NHL) is still under dispute. We performed this study to examine the association between DM and subsequent NHL risk. Methods: A systematically search had been performed in PubMed, EmBase, and the Cochrane Library to identify eligible studies from inception to September 2018. Results: Thirteen cohort studies were included, with a total of 9024761 part…

Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.

International journal of radiation oncology, biology, physics · 2014 · PMID 24725689

Radiation therapy (RT) is the most effective single modality for local control of non-Hodgkin lymphoma (NHL) and is an important component of therapy for many patients. Many of the historic concepts of dose and volume have recently been challenged by the advent of modern imaging and RT planning tools. The International Lymphoma Radiation Oncology Group (ILROG) has developed these guidelines after multinational meetings and analysis of available evidence. The guidelines represent an agreed consensus view of the ILRO…

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients.

Medicine · 2017 · PMID 28858138

BACKGROUND: Non-Hodgkin lymphoma (NHL) is a group of lymphoproliferative malignancies with varying treatment responses and progression-free survival (PFS) times. The objective of this study was to quantify the effect of treatment and patient-population characteristics on PFS in patients with NHL. METHODS: A database was developed from 513 NHL clinical trials reported from 1993 to 2015. Summary-level PFS was obtained from 112 of these trials, which included 155 cohorts and 11,824 patients. Characteristics evaluated …

Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma.

Journal of computer assisted tomography · 2017 · PMID 27560022

PURPOSE: This study aimed to systematically review the additional value of F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to computed tomography (CT) for staging newly diagnosed follicular lymphoma in terms of Ann Arbor staging and Follicular Lymphoma International Prognostic Index (FLIPI) risk stratification. MATERIALS AND METHODS: The PubMed/MEDLINE database was searched for relevant original studies. Included studies were methodologically assessed. Data on the frequency of FDG-PET-induced chan…

Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.

Cancer · 2024 · PMID 38041532

BACKGROUND: The emergence of novel and efficient antibody maintenance approaches has provided more options for post-induction treatment of advanced follicular lymphoma (FL), and further comparisons are required to determine the most clinically beneficial regimen. The authors conducted a systematic review and meta-analysis to evaluate the maintenance or consolidation strategy. METHODS: The authors performed two independent searches in PubMed, Web of Science, the Cochrane library databases, Scopus, and Embase for ran…

A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.

The oncologist · 2024 · PMID 38207010

PURPOSE: The clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 signaling and DNA damage from ionizing radiation. In 2002, the first RIT was approved by the U.S. Food and Drug Administration for the treatment of patients with indolent B-cell follicular non-Hodgkin lymphoma (NHL). The 2 approved agents, 90 Y-ibritumomab tiuxetan (90Y-IT, Zevalin, Acrotech Biophar…

Non-Hodgkin's lymphomas (NHL).

Acta oncologica (Stockholm, Sweden) · 1996 · PMID 9154102

This synthesis of the literature on radiotherapy for non-Hodgkin's lymphomas is based on 158 scientific articles, including 16 randomized studies, 18 prospective studies, and 90 retrospective studies. These studies involve 14,137 patients. Non-Hodgkin's lymphomas are highly radiosensitive, and local recurrence following radiotherapy is unusual. Radiotherapy probably cures approximately 50% of both low-grade and high-grade malignant NHL at stage I. Involved field is apparently sufficient, however, higher doses are r…

Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.

Hematological oncology · 2019 · PMID 31418878

The CD-20 antibody rituximab is a standard component of treatment of non-Hodgkin B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). Primary DLBCL of the central nervous system, also called primary central nervous system lymphoma (PCNSL), is a DLBCL confined to the central nervous system. There has been debate whether intravenous rituximab accumulates sufficiently in the central nervous system to exert an effect. In this systematic review, we assess the benefits and harms of rituximab in the treatmen…

Treatment of Parotid Non-Hodgkin Lymphoma: A Meta-Analysis.

Journal of global oncology · 2018 · PMID 30241143

PURPOSE: This meta-analysis aimed to review the published outcomes of parotid non-Hodgkin lymphoma (NHL) pertaining to different treatment modalities. MATERIALS AND METHODS: A total of 48 journal articles published between 1993 and 2015, comprising 742 cases of parotid NHL, were initially evaluated. In total, 108 patients from 12 studies who had sufficient data for analysis, including age, tumor histopathology, treatment modality, and outcome at final follow-up, were included. Patients were randomly assigned to dif…

Exposure to glyphosate and risk of non-Hodgkin lymphoma: an updated meta-analysis.

La Medicina del lavoro · 2021 · PMID 34142676

OBJECTIVE: We updated a recent systematic review and meta-analysis of epidemiologic studies to help clarifying the association between exposure to glyphosate and risk of non-Hodgkin lymphoma (NHL). METHODS: We conducted an updated search of the literature, and identified a total of 15 relevant publications, from which we extracted results from six non-overlapping studies. We performed random-effects meta-analyses for ever-exposure to glyphosate, dose-response, and risk of specific NHL subtypes Results: The meta-RR …

A systematic review and meta-analysis of occupational exposures and risk of follicular lymphoma.

Environmental research · 2021 · PMID 33607095

BACKGROUND: The etiology of follicular lymphoma (FL), a common non-Hodgkin lymphoma subtype, is largely unknown. OBJECTIVE: We performed a systematic review and meta-analysis of observational studies examining the relationship between occupational exposures and FL risk. METHODS: We searched Ovid MEDLINE, Ovid EMBASE, and Web of Science for eligible observational studies examining job titles or occupational exposures prior to January 1, 2020. We performed a narrative synthesis and used random-effects models to gener…

Guidelines for the management of diffuse large B-cell lymphoma.

British journal of haematology · 2016 · PMID 27196701

Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis.

Leukemia research · 2021 · PMID 34052662

Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage of patients who may relapse or be refractory. In this sense, new therapeutic options have emerged in the search for adequate responses, such as monoclonal antibodies that target the CD20 molecule. Another valid option is radioimmunotherapy (RIT), which combines using monocl…

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.

Cancer science · 2021 · PMID 33938097

Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conversely, some drugs are removed by HD and may expose the patient to undertreatment, therefore the timing of drug administration in relation to HD sessions must be carefully planned. Also, the metabolites of some drugs show …

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.

Blood cancer journal · 2022 · PMID 34987165

Front-line treatment for follicular lymphoma has evolved with the introduction of maintenance therapy, bendamustine (Benda), obinutuzumab (G), and lenalidomide (Len). We conducted a random-effects Bayesian network meta-analysis (NMA) of phase 3 randomized controlled trials (RCTs) to identify the regimens with superior efficacy. Progression-free survival (PFS) was compared between 11 modern regimens with different immunochemotherapy and maintenance strategies. G-Benda-G resulted in with the best PFS, with an HR of 0…

Prognostic Value of Microvessel Density in Non-Hodgkin Lymphoma: A Meta-Analysis.

Acta haematologica · 2021 · PMID 34044389

BACKGROUND: Angiogenesis in non-Hodgkin lymphoma (NHL) has been investigated by a variety of studies. However, the correlation between angiogenesis and the occurrence or prognosis of NHL patients remains controversial. METHODS: We performed a systematic and comprehensive retrieval of relevant literatures from PubMed, EMBASE, and Web of Science databases. The quality of the eligible studies was assessed using the Newcastle-Ottawa Scale (NOS). RESULTS: Fifteen eligible studies containing a total of 1373 NHL patients …

Diesel exhaust exposure and risk of non-Hodgkin lymphoma: a meta-analysis.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2022 · PMID 34750336

OBJECTIVE: We aimed at carrying out a systematic review and meta-analysis of epidemiological studies on the association between occupational and non-occupational exposures to diesel exhaust and risk of non-Hodgkin lymphoma. METHODS: We conducted a systematic search of the literature and identified 16 cohort studies and 7 case-control studies that analyzed non-Hodgkin lymphoma alone or combined with Hodgkin lymphoma or multiple myeloma, from which we extracted 29 independent risk estimates. We performed random-effec…

Interferon-alpha for maintenance of follicular lymphoma.

The Cochrane database of systematic reviews · 2010 · PMID 20091564

BACKGROUND: Indolent non-Hodgkin's lymphoma, in particular follicular lymphoma (FL), is characterized by multiple remissions and relapses. Several studies have used interferon-alpha (IFN) to control this disease, both as induction and as maintenance therapy. It is not yet clear whether IFN can be associated with a survival benefit although it may prolong progression-free survival. OBJECTIVES: To determine the effects of IFN in the maintenance therapy of FL. SEARCH STRATEGY: We searched the Cochrane Central Register…

Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.

European journal of haematology · 2017 · PMID 27943422

This study aimed to systematically review and meta-analyze the value of pretransplant FDG-PET in predicting outcome after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma. MEDLINE was systematically searched; included studies were methodologically assessed and meta-analyzed, when possible. Overall methodological quality of included studies (n = 11) was poor, with moderate risk of bias in the domains of study participation (n = 7) and prognostic factor measurement (n = 7), and high risk of bia…

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics · 2026 · PMID 41785936

Extranodal natural killer/T-cell lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. These evidence-based recommendations for natural killer/T-cell lymphoma by the American Radium Society were developed by a multidisciplinary panel of medical and radiation oncologists to propose treatment approaches. This guideline was based on a literature review with a consensus methodology to rate the appropriateness of treatment recommendations for each natural killer/T-cell lymphoma clinical presentation. Six va…

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026 · PMID 42323047

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next…

Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis.

BMC cancer · 2026 · PMID 42332608

BACKGROUND: The survival rate for hematologic malignancies is steadily improving. With the encouraging trend and the aging of these survivors, there is an ever-increasing responsibility for identifying adverse cardiovascular outcomes associated with carcinogenesis and/or anti-cancer therapies across the span of their lives. However, prospective studies have yielded inconsistent results. METHODS: We performed a meta-analysis to summarize the evidence regarding the association between leukemia, Hodgkin lymphoma (HL),…

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.

Blood cancer journal · 2026 · PMID 42362499

Pola-R-CHP regimen is the new standard of care for untreated diffuse large B-cell lymphoma (DLBCL) patients, following the POLARIX trial. This study evaluates whether clinical trial (RCT) efficacy and safety are reproducible in real-world evidence (RWE) settings. This systematic review and meta-analysis compared outcomes between RCTs and RWE studies. Primary endpoints were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Meta-regression explored heterogeneity using age, Inter…

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42177127

INTRODUCTION: Survival outcomes of patients with mantle cell lymphoma (MCL) have substantially improved. In the setting of extended overall survival (OS), progression-free survival (PFS) is typically used as a primary endpoint in MCL clinical trials rather than OS to limit trial duration and cost. However, no prior analysis has assessed whether PFS can reliably predict OS. The aim of this study is to perform a systematic evaluation of PFS as a surrogate endpoint for OS in phase III MCL clinical trials. MATERIALS AN…

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.

Frontiers in immunology · 2026 · PMID 42495620

This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neuroto…

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology · 2026 · PMID 42313425

IMPORTANCE: T-cell-engaging bispecific antibodies (BsAbs) are increasingly used in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). As these agents transition into earlier courses of therapy and broader clinical use, understanding their safety profile is critical. While second primary malignant neoplasms (SPMs) represent a key long-term safety signal, small sample sizes, single-arm trials, short follow-up, and heterogeneous reporting have limited reliable estimation of their frequency. OBJECTIVE: To est…

Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.

Acta neurologica Belgica · 2026 · PMID 41212511

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…

Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.

PeerJ · 2026 · PMID 42428526

BACKGROUND AND OBJECTIVES: Large B-cell lymphoma (LBCL) is a common and aggressive non-Hodgkin lymphoma (NHL) characterized by abnormal proliferation of mature B lymphocytes, with a 10-year prevalence of up to 45 cases per 100,000 individuals in European populations and a continuing upward trend. Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) are the two most established chimeric antigen receptor T-cell (CAR-T) therapy products for LBCL, yet a systematic comparison of their efficacy and safety in…

CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.

La Clinica terapeutica · 2026 · PMID 42340791

BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…

Efficacy of zanubrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.

Critical reviews in oncology/hematology · 2026 · PMID 41786108

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, and previous studies have indicated the potential of zanubrutinib in the treatment of DLBCL. This meta-analysis aims to evaluate the efficacy of zanubrutinib in DLBCL patients and further explore potential differences in treatment effects across diverse patient subgroups. METHODS: A systematic literature search was conducted using two major databases (PubMed and Embase) and four key conference websites to e…

Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.

Cancer · 2026 · PMID 42487493

BACKGROUND: Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts. METHODS: The authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus…

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352

INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674

The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …

An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

Journal of medical economics · 2026 · PMID 42452801

OBJECTIVE: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL). METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC). RESULTS: After matching selected covariates, statistically significant differences were observed with zanu…

Clinical outcomes of Epstein-Barr virus infection/reactivation following CAR-T cell therapy: A systematic review.

Transplant immunology · 2026 · PMID 42442615

BACKGROUND: Epstein-Barr virus (EBV) infection or reactivation is an emerging but underrecognized complication following chimeric antigen receptor T-cell (CAR-T) therapy and is likely associated with treatment-induced immune dysregulation. Data regarding its clinical impact remain limited. OBJECTIVE: To evaluate the reported occurrence, clinical manifestations, and outcomes of EBV infection or reactivation in adults undergoing CAR-T therapy. METHODS: A systematic review was conducted in accordance with the PRISMA 2…

[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · PMID 42409743

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes re…

Single-cell RNA sequencing unveils CD8+ T cell heterogeneity in the diffuse large B-cell lymphoma microenvironment: A systematic review.

Critical reviews in oncology/hematology · 2026 · PMID 42144172

BACKGROUND: The heterogeneous response to immunotherapy in diffuse large B-cell lymphoma (DLBCL) is largely attributable to the diverse functional states of CD8⁺ T cells within the tumor microenvironment. Although single-cell RNA sequencing (scRNA-seq) has revolutionized cellular resolution, a systematic synthesis of this evidence to map CD8⁺ T cell heterogeneity and its clinical implications in DLBCL is currently lacking. METHODS: Following the PRISMA guidelines and a PROSPERO-registered protocol (CRD420261282336)…

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England) · 2026 · PMID 42217458

BACKGROUND: Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. METHODS: frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 29…

Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.

Journal of comparative effectiveness research · 2026 · PMID 42359923

Aim: Several CAR-T cell therapies have received regulatory approval from both the US FDA and the EMA for the treatment of large B-cell lymphoma. However, direct comparative trials between CAR-T cell therapies are lacking, mainly due to different clinical development timelines and availabilities as well as substantial resource requirements and difficulties in recruiting sufficiently large and homogeneous cohorts from a highly pre-treated patient population. Consequently, indirect treatment comparisons (ITCs) play a …

Rescue Protocols for Canine Non-Indolent B Cell Lymphoma: A Systematic Review.

Veterinary and comparative oncology · 2026 · PMID 41656180

Canine lymphoma is a heterogenous group of diseases. The most common subtype is diffuse large B cell lymphoma (DLBCL), though definitive diagnosis beyond non-indolent = multicentric B cell lymphoma is not often achieved in clinical practice as it requires histopathology. Most dogs respond well to standard-of-care multiagent chemotherapy (CHOP) but relapse and eventual CHOP-resistance is likely. Less commonly there is a lack of complete response to initial CHOP treatment. CHOP-resistant cases are treated with rescue…

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.

Journal of cellular and molecular medicine · 2026 · PMID 42687221

Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment-naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta-analysis was intended to evaluate their efficacy, addressing critical gaps in clinical decision-making. We systematically searched PubMed, Embase, and Cochrane up to January 2025 for studies (RCT/single-arm) assessing the efficacy of BTKis in MCL pa…

Antibody-drug conjugate development in lymphoma: a systematic clinical trial landscape analysis.

Frontiers in immunology · 2026 · PMID 42620849

INTRODUCTION: Antibody-drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate development trends, evidence maturity, molecular architecture, combination strategies, inactive development, and safety reporting. METHODS: We searched Trialtrove for Phase I-IV interventional trials evaluating at least one ADC in lymphoma, with actual or anticipated star…

Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review.

Frontiers in immunology · 2026 · PMID 42643454

BACKGROUND: Hematologic neoplasms remain a growing global burden, with relapse, resistance, and limited treatment options persisting. Bispecific antibodies (BsAbs) offer a novel multi-antigen targeting strategy. This systematic review assesses their efficacy and safety, offering an in-depth appraisal of their therapeutic potential and the unmet medical needs. METHODS: We conducted this systematic review following the PRISMA 2020 guidelines. Articles published up to 20 June 2026 were searched across PubMed, Scopus, …

An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

Journal of medical economics · 2026 · PMID 42452801

OBJECTIVE: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL). METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC). RESULTS: After matching selected covariates, statistically significant differences were observed with zanu…

The surgery for the patients with intestinal non‑Hodgkin lymphomas: a nationwide study.

Annals of medicine · 2026 · PMID 41732903

BACKGROUND: The treatment strategy for intestinal non-Hodgkin lymphoma (NHL) and the role of surgery warrant reevaluation. METHODS: This study analyzed clinical data from a cohort of 12,047 patients diagnosed with intestinal NHL, extracted from the Korean National Health Insurance System database between 2002 and 2021. RESULTS: Among these patients, 3,566 (29.6%) were categorized into the surgery group, while 8,481 (70.4%) were included in the nonsurgery group. Surgery was independently associated with both prolong…

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

Oncoimmunology · 2026 · PMID 42415230

Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R2) for R/R FL. Epcoritamab + R2 pivotal data dem…

Baseline Risk of Treatment Abandonment and Survival of Children With Common and Curable Cancers in the Zero Abandonment Cash Transfer Programme-A Multi-Centre Prospective CANCaRe Africa Study.

Pediatric blood & cancer · 2026 · PMID 42578510

BACKGROUND: The WHO Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common and curable cancers. This study assessed the risk of treatment abandonment (TxA) and the impact on survival of five of these cancers in sub-Saharan Africa in preparation for a cash transfer intervention. METHODS: This multi-centre, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphobla…

An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 42584691

OBJECTIVES: To develop an individualized nomogram for predicting disease progression risk in systemic anaplastic large cell lymphoma (sALCL). METHODS: Independent predictors of progression-free survival (PFS) were identified using Cox regression in a multicenter retrospective cohort of 109 sALCL patients (2010-2022). These were incorporated into a three-factor nomogram, evaluated via bootstrapped internal validation (1000 resamples), ROC analysis, C-index, decision curve analysis (DCA), and clinical impact curve (C…

Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.

Annals of medicine · 2026 · PMID 42482660

BACKGROUND: CD5-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype with poor outcomes. Following the approval of Pola-R-CHP in China, this study aimed to evaluate its efficacy as initial therapy for this high-risk population. METHODS: We conducted a multicenter, retrospective study of previously untreated CD5-positive DLBCL patients who received Pola-R-CHP as first-line therapy between April 2023 and February 2025. Treatment response was assessed by PET/CT after 3 cycles and at the end of treat…

Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control.

Cancer biology & therapy · 2026 · PMID 42015349

INTRODUCTION: The selection of an optimal maintenance agent in diffuse large B-cell lymphoma (DLBCL) continues to pose a significant clinical challenge. This study aims to evaluate the prognostic impact of maintenance therapy (MT) in DLBCL. METHODS: We conducted a retrospective analysis of data from DLBCL patients undergoing first-line MT at four hospitals in Beijing between January 2019 and August 2024. The REMoDL-B trial database was selected as the control group. RESULTS: The MT group comprised 106 cases and a m…

Survival and prognostic features of early-stage diffuse large B-cell lymphoma in older adults.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 41922932

BACKGROUND: Early-stage diffuse large B-cell lymphoma (ESDLBCL) in older adults is understudied, and existing prognostic tools such as the stage-adjusted International Prognostic Index (Sa-IPI) may not adequately account for comorbidity and age-related vulnerability. This study evaluated long-term outcomes and developed a simplified prognostic index for patients aged ≥ 60 years with ESDLBCL. METHODS: We retrospectively analyzed adults aged ≥ 60 years with stage I-II DLBCL treated at King Hussein Cancer Center betwe…

AI for prognostic assessment of diffuse large B-cell lymphoma using H&E whole-slide images.

HemaSphere · 2026 · PMID 42676952

Prediction of the outcome of large B-cell lymphomas/high-grade B-cell lymphomas (DLBCLs/HGBCLs) is based on clinical parameters and molecular testing, for example, for rearrangements of MYC (MYC-R) and MYC-R in combination with BCL2 and BCL6 translocations (double/triple hit). However, the group of DLBCL/HGBCL with poor outcome is not confined to MYC-R lymphomas, and fluorescence in situ hybridization (FISH) testing for MYC-R misses several high-risk lymphomas. We aimed to understand if artificial intelligence (AI)…

Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma.

Journal of the National Cancer Institute · 2026 · PMID 42679364

BACKGROUND: Opioid exposure during cancer treatment is common and leads to new persistent opioid use (NPOU) in a subset of patients. There are limited data on the incidence and predictors of NPOU among patients with diffuse large B-cell lymphoma (DLBCL). METHODS: We conducted a population-based cohort study including patients with DLBCL ≥18 years old from Ontario, Canada who received first-line rituximab-based chemoimmunotherapy from 2014-2021 and survived >365 days after treatment. We defined opioid exposure as fi…

Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare.

Journal of medical economics · 2026 · PMID 41941177

BACKGROUND: Rituximab-pvvr (Ruxience), -abbs (Truxima), and -arrx (Riabni) are biologic therapies approved by the United States Food and Drug Administration (FDA) as biosimilars to originator rituximab (Rituxan). Each is approved for the treatment of diffuse large B-cell lymphoma (DLBCL) in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). The objective of this study is to explore the cost-efficiency and budget-neutral expanded access of conversion to first-line biosimilar rituxima…

Apoptosis-related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 41635044

OBJECTIVES: Dysregulation of apoptosis-related genes (ARGs) may contribute to tumorigenesis and impact patient prognosis, but their specific influence on prognosis and immune characteristics in diffuse large B-cell lymphoma (DLBCL) remains unclear. METHODS: Gene expression profiles were collected from GEO datasets GSE10846 (training set; n = 414) and GSE181063 (validation set; n = 1310), totaling 1724 DLBCL samples. Univariate Cox and LASSO Cox regression analyses were performed to identified key ARGs, which were u…

Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population.

Journal of medical economics · 2026 · PMID 41705966

AIM: Conventional therapies in Japan for relapsed or refractory large B-cell lymphoma (r/r LBCL) require intravenous infusion (IV), while epcoritamab is administered subcutaneously. Despite the expected quality of life (QOL) improvement from reduced drug administration burden, limited data exists on QOL for common r/r LBCL treatment modalities. This study aimed to estimate the impact of drug administration on QOL (i.e. process utility) across treatments for r/r LBCL using responses from the Japanese general populat…

Epidemiology and outcomes of invasive fungal infections in patients with mature T-cell and NK-cell lymphomas.

Annals of medicine · 2026 · PMID 42644346

BACKGROUND: Invasive fungal infection (IFI) causes poor outcomes in haematological malignancies, but data in mature T-cell and NK-cell lymphomas (T/NKCL) are scarce. We aimed to define epidemiology and outcomes of IFI in this population. MATERIALS AND METHODS: This retrospective study enrolled adult patients with T/NKCL between 2019 and 2024. Proven and probable IFI were defined according to the 2020 EORTC/MSGERC criteria. Multivariable logistic regression was used to identify factors associated with IFI and death.…

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.

International journal of cancer · 2026 · PMID 41999193

To evaluate the efficacy and safety of the RMT regimen as first-line induction therapy for primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), we retrospectively analyzed 36 patients treated with 4-6 cycles of RMT. After 4 induction cycles, the overall response rate and complete response rate were 97.2% and 80.6%, respectively. With a median follow-up of 19.9 months, the 2-year progression-free survival (PFS) and overall survival rates were 64.4% and 79.3%. The 2-year PFS was 100% in patients…

Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal - A modeling approach.

Journal of medical economics · 2026 · PMID 42596901

AIM: This study aimed to quantify the health benefits that can be achieved by treating axicabtagene-ciloleucel (axi-cel)-eligible large B-cell lymphoma patients with axi-cel instead of historical standard of care (hSoC) in Portugal. "Estimated Opportunity Lost" quantified the difference in outcomes in 2024 if all axi-cel-eligible patients were treated with axi-cel versus if only a fraction received axi-cel and the remaining patients received hSoC. "Potential Future Gains" quantified the difference in outcomes in 20…

Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 42071165

OBJECTIVES: Lactylation and liquid-liquid phase separation related genes have been reported to be associated with tumor prognosis and immunity, but their specific influence on the prognosis and immune characteristics of diffuse large B-cell lymphoma (DLBCL) remains unclear. METHODS: GSE56315 (33 control samples and 55 DLBCL patient samples) has been used to screen for lactylation and liquid‒liquid phase separation related differentially expressed genes (LLRDEGs). Based on the optimal cutoff, LLRDEGs associated with…

Clinical features of primary intestinal follicular lymphoma: A single-center retrospective study.

The Journal of international medical research · 2026 · PMID 42669783

ObjectiveTo characterize the clinical features of primary intestinal follicular lymphoma and provide insights into its diagnosis and management.MethodsWe retrospectively analyzed the clinical, endoscopic, imaging, pathological, and long-term follow-up data of eight patients with primary intestinal follicular lymphoma who were admitted between January 2019 and August 2025.ResultsThe mean patient age was 58.13 years, and 75.00% of patients were women. Abdominal pain (62.50%) was the most common clinical manifestation…

Interim Positron Emission Tomography-Guided Dose-Adapted Residual Site Radiation Therapy Improves Survival in Diffuse Large B-Cell Lymphoma Patients With Partial Metabolic Response After R-CHOP: A Retrospective Cohort Analysis.

Advances in radiation oncology · 2026 · PMID 42440462

PURPOSE: Optimal management of diffuse large B-cell lymphoma (DLBCL) patients achieving partial remission (Deauville 5-point scale [5PS]: 4-5) with interim positron emission tomography (iPET) is undefined. This study evaluated iPET-guided, dose-adapted residual site radiation therapy (RSRT) outcomes. METHODS AND MATERIALS: Retrospective analysis of 68 DLBCL patients with iPET 5-PS 4 to 5 after 4 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) cycles was conducted. Twenty-nine patients…

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia.

Annals of medicine · 2026 · PMID 41797694

BACKGROUND: Histologic transformation from Waldenström macroglobulinemia (WM) to diffuse large B-cell lymphoma (DLBCL) is a rare but clinically challenging event. METHODS: In this retrospective study, we analyzed 15 cases of histologic transformation among WM patients treated at the Department of Hematology, Jiangsu Province Hospital, between October 2015 and February 2025. RESULTS: The median age at transformation was 67 years, with a median time from initial WM diagnosis to transformation of 8 months (range: 0-17…

CAR T therapy in adult DLBCL patients in Slovenia: Evaluation of predictive scores for outcomes and adverse events.

Human vaccines & immunotherapeutics · 2026 · PMID 41614438

CAR T cell therapy is a promising immunotherapy for hematologic malignancies, yet early prediction of outcomes and adverse events remains difficult, especially in small real-world cohorts. We retrospectively analyzed 14 adult patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR T cells in Slovenia, assessing IL-6 increase rates and established predictive metrics including EASIX-C, CAR-HEMATOTOX, and IBPS on Day -5 (pre-lymphodepletion) and Day 0 (infusion). Contrary to our expectation, an inverse co…

CHAF1A identified as a candidate biomarker and potential therapeutic target in Burkitt lymphoma through integrated bioinformatics and histopathological analysis.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 42535765

BACKGROUND: Burkitt lymphoma (BL) is a highly aggressive malignancy with limited effective treatments due to toxicity/resistance. Identifying and prioritizing candidate biomarkers and potential therapeutic targets from complex transcriptomic data, ahead of functional validation, remains a major unmet need. METHODS: We integrated differential gene expression analysis across BL vs. control cohorts (Gene Expression Omnibus [GEO] datasets GSE43677/GSE12453) with Random Forest machine learning to prioritize candidates. …

Prognostic value of the CONUT score in newly diagnosed diffuse large B-cell lymphoma.

Oncology letters · 2026 · PMID 42614724

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and clinical outcomes remain heterogeneous despite standard R-CHOP therapy. The Controlling Nutritional Status (CONUT) score, an immunonutritional index based on serum albumin, total cholesterol and lymphocyte count, has emerged as a potential prognostic marker in this setting. In this retrospective observational study, the prognostic value of the pre-treatment CONUT score was evaluated in 110 adult patients with newly diagnose…

Characteristics and prognosis of Epstein Barr virus-positive diffuse large B-cell lymphoma: a retrospective, single-center study.

Hematology (Amsterdam, Netherlands) · 2026 · PMID 41668558

OBJECTIVE: To analyze the clinical characteristics and prognosis of Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) in a Chinese cohort. METHODS: Fifty-seven EBV+DLBCL patients (diagnosed between 2013 and 2020) and 228 EBV-negative DLBCL (EBV-DLBCL) controls were included. Differences were compared and prognostic factors were identified using univariate and multivariate analysis. RESULTS: EBV+DLBCL patients (median age, 56 years; 38 men [66.7%]) predominantly had non-GCB origin (70.2%). Compar…

Evaluating the Readability of Patient-Facing Online Educational Materials for Pediatric Leukemia and Lymphoma.

Pediatric blood & cancer · 2026 · PMID 42533591

BACKGROUND: Together, leukemia and lymphoma account for 38.7% of newly diagnosed pediatric cancer cases in the United States each year. Many caregivers utilize online resources to inform medical health decisions. Understanding the readability of these materials is critical to ensuring comprehensible patient education. We sought to evaluate if the readability of online patient-facing educational materials concerning pediatric leukemia and lymphoma met the recommended sixth-grade reading level by the National Institu…

Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis.

Frontiers in veterinary science · 2026 · PMID 42656497

BACKGROUND: Canine lymphoma (cL), the second most common canine cancer after mammary carcinoma, presents therapeutic challenges due to limitations of conventional regimens, necessitating novel therapeutic approaches. Tyrosine kinase inhibitors (TKIs), which have demonstrated efficacy in human non-Hodgkin lymphoma (NHL), are increasingly being investigated as targeted therapies for cL, which also serves as a valuable translational model for NHL research. OBJECTIVES: To systematically evaluate the efficacy of TKIs in…

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer · 2026 · PMID 42413982

BACKGROUND: Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies. GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (A…

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42336688

BACKGROUND: Preclinical data support the combination of venetoclax and copanlisib in specific genomic subgroups of diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: In this investigator-initiated, phase I, multicenter trial we aimed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of copanlisib and venetoclax in patients with relapsed/refractory (R/R) DLBCL. Key eligibility criteria included relapse after or noncandidate for autologous stem cell transplantation or chimeri…

Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial.

The oncologist · 2026 · PMID 42438166

BACKGROUND: Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R NKTCL) remains a highly lethal disease, particularly after failure of PD-1 blockade-based therapy. Preclinical data suggest that inhibition of exportin-1 (XPO1) may enhance antitumor immunity and synergize with PD-1 blockade. PATIENTS AND METHODS: We conducted a multicenter, open-label phase 1b study (TOUCH, Arm C) evaluating selinexor plus tislelizumab in patients with R/R NKTCL previously treated with L-asparaginase-containing regim…

Comprehensive phenotypic and clonality analysis of intraepithelial lymphocytes of intestinal T-cell lymphoma and chronic enteropathy in dogs.

Veterinary pathology · 2026 · PMID 41913572

Canine intestinal T-cell lymphoma (ITCL) may arise from intraepithelial lymphocyte (IEL) subsets expanded in chronic enteropathy (CE). To investigate this potential cell of origin, we performed flow cytometry, immunohistochemistry, and RNA in situ hybridization on IELs using biopsy samples from 62 dogs, including 6 large-cell lymphomas (LCLs), 9 small-cell lymphomas (SCLs), 31 CEs with increased IELs (IEL+CE), and 16 CEs without increased IELs (IEL-CE). IELs in ITCLs were predominantly CD4-CD8α- (LCL, 5/6; SCL, 4/9…

Mouse models of B cell lymphomas on the basis of genetic features.

Frontiers in immunology · 2026 · PMID 42614320

Diffuse large B cell lymphoma (DLBCL) is a highly aggressive form of lymphoma that is genetically and phenotypically diverse. Most DLBCLs arise from the germinal center and transcriptionally represent either germinal center or post-germinal center activated B cells by gene expression profiling. Recently, a revised classification of DLBCLs has identified at least six molecularly defined groups based on their genomic landscape. In this review, we discuss the use of transgenic animal models to study DLBCLs based on th…

Chemical Exposures, DNA Methylation and Whole Blood DNA Damage in Pet Golden Retrievers.

Veterinary and comparative oncology · 2026 · PMID 42003040

Canine multicentric lymphoma (CL) is a common and typically fatal cancer among dogs. Although certain breeds have a higher incidence of CL, its environmental risk factors remain uncertain. Exposures to herbicides and volatile organic compounds (VOCs) associate with non-Hodgkin lymphoma in people. These exposures also correlate with measurable in vivo DNA strand breaks in dogs, even at estimated systemic concentrations that do not reach genotoxic thresholds. Herbicides and VOCs can also exert genotoxicity through di…

Central nervous system lymphoma and neurolymphomatosis in equids.

Journal of veterinary internal medicine · 2026 · PMID 42525884

BACKGROUND: Lymphoma affecting the central and peripheral nervous systems in equids is rarely reported. HYPOTHESIS/OBJECTIVES: To describe the clinical presentation, neuroanatomical localization, laboratory and pathologic features, type of lymphoma, and outcome to further current knowledge. ANIMALS: Fourteen equids (13 horses, 1 mule). METHODS: Retrospective study. Medical records from a veterinary teaching hospital were reviewed (1993-2025). The inclusion criteria consisted of a definitive diagnosis of lymphoma of…

The RNA-binding activity of the Drosophila Brat protein is necessary for viability and mRNA regulation.

RNA biology · 2026 · PMID 42206510

Brain tumor (Brat) is a Drosophila TRIM-NHL protein required for embryogenesis and neural stem cell differentiation. Although structural and biochemical studies established that the Brat NHL domain specifically binds RNA, the in vivo requirement for this activity has not been directly tested. Here, we used structure-guided mutagenesis and genome engineering to determine whether RNA recognition is essential for Brat function during development. The direct interaction between Brat's NHL domain and RNA containing Brat…

Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.

Oncoimmunology · 2026 · PMID 42557693

Tumor-induced manipulations of myelomonocytic differentiation have been widely reported. Here, we describe the elicitation of a tumor-supportive cell type in a T lymphoma model in mice. We observed that the development of T lymphoma coincided with the appearance of a lymphoma-associated monocytic cell type (LAM) of host origin accompanied by a diminished dendritic cell (DC) population. RNA-sequencing and cytometric analyses revealed that LAMs shared markers with both DCs and with resident macrophages, most closely …

Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42148884

PURPOSE: Many patients with various cancer types have received immune checkpoint inhibitors (ICI) worldwide since their approval, and novel unexpected complications from their long-term use are apparent. We identified some cases of B-cell lymphoma occurring during PD-1 blockade therapy as such unexpected complications. In this study, we aimed to evaluate the incidence of hematologic malignancies in patients with lung cancer receiving PD-1 blockade therapy and to elucidate the mechanisms underlying the progression o…

LncRNA IRENA promotes peripheral T-cell lymphoma progression through scaffolding ARHGEF1 and FMNL1 to modulate RHOA GTPase/MAPK signaling.

Oncogene · 2026 · PMID 42373804

Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous group of lymphomas, characterized by aggressive behavior and poor outcomes. Investigating the key regulatory long non-coding RNAs (lncRNAs) is helpful to refine current prognostic models and identify novel therapeutic targets in PTCL. Using clinical and transcriptomic data from 172 patients (training cohort) and 36 patients (validation cohort) with newly diagnosed nodal PTCL, this study identified LINC01727 (also known as IRENA) as an independent prognosti…

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Annals of hematology · 2026 · PMID 42380537

Secondary central nervous system involvement (sCNSi) is a fatal complication of diffuse large B-cell lymphoma (DLBCL), yet its molecular determinants remain poorly understood. To investigate the mechanisms underlying CNS-preferential dissemination, we established an in vivo DLBCL xenograft model using two representative cell lines, OCI-LY19 and Toledo, followed by transcriptomic profiling of lymphoma cells isolated from the brain, peripheral organs, and parental cultures. Transcriptomic analyses revealed gene signa…

Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.

Clinical and translational medicine · 2026 · PMID 42613996

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. METHODS: In this study, we analysed a real-world cohort of 178 newly diagnosed DLBCL patients homogeneously treated with R-CHOP-like regimens, integrating RNA sequencing, targeted mutational profiling and digital deconvolution using the EcoTyper algorithm. RESULTS: Five malignant B-cell states (S1-S5) were identified, each reflecting distinct differentiation and transcriptional programs with prognostic relevanc…

Diverse transcriptomic and mutational patterns but limited functional pathway alterations in patient-derived Sézary syndrome cells.

The Journal of investigative dermatology · 2026 · PMID 41644084

Eradication of Sézary syndrome (SS) is hampered by genetic and molecular heterogeneity. A better understanding of the putative commonalities underlying SS oncogenicity may help to provide more efficient therapies against this disease. This work analyzes the whole transcriptome of different patient-derived SS cells (n = 7) to identify expression patterns and mutational profiles that may provide clues on new therapeutic options for patients with SS. Mononuclear cells were recovered by Ficoll gradient from fresh perip…

DNA Replication Stress-Induced Transcriptome of Human Burkitt's Lymphoma Identifies Reciprocal Regulation Between MBD1 and BCL6 During Germinal Center-Derived B-Lymphomagenesis.

Hematological oncology · 2026 · PMID 42563211

BCL6 is a master transcriptional regulator of germinal center (GC) B cells. BCL6 is frequently translocated at the major translocation cluster (MTC) within intron 1 of the BCL6 locus, a hotspot commonly rearranged in diffuse large B cell lymphomas (DLBCLs). BCL6 amplifications are associated with therapeutic resistance and poor survival outcomes in hematological and solid cancers. However the mechanisms suppressing genome instability at the BCL6-MTC preventing BCL6 rearragements remain unclear. Here, transcriptome …

Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis via lncRNA ADPGK-AS1 downregulation.

Journal of enzyme inhibition and medicinal chemistry · 2026 · PMID 42295078

Shikonin, a natural compound, exhibits antitumor effects in DLBCL, but its mechanism remains unclear. Shikonin's cytotoxicity in DLBCL cells was assessed by MTT assays. Ferroptosis and lipid peroxidation markers were analysed via flow cytometry and biochemical kits. Mechanisms were explored using gene knockdown/overexpression, dual-luciferase assays, RNA pull-down, proteomics, RIP, FISH, and ChIP. Key proteins and genes involved in ferritinophagy and ferroptosis were examined by Western blot, RT-qPCR, and immunoflu…

NAD+ precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCL.

Pharmaceutical science advances · 2026 · PMID 41993707

Natural killer (NK) cells play a key role in the standard treatment of diffuse large B-cell lymphoma (DLBCL). However, NK cells in DLBCL patients frequently display an exhausted phenotype, which is associated with poor clinical outcomes. The metabolic mechanisms contributing to this functional impairment remain poorly understood. We assessed degranulation (CD107a), cytokine secretion (IFN-γ, TNF-α), mitochondrial activity, and lipid metabolism in NK cells from DLBCL patients and healthy donors. Dysregulated lipid s…

Ferroptosis-STING co-activation drives GzmB+CD38+CD8+ T-cell expansion to overcome lymphoma immunosuppression.

Biomaterials · 2026 · PMID 42061111

The immunosuppressive tumor microenvironment (TME) of B-cell lymphoma limits the efficacy of conventional chemotherapy and hampers the full activation of antitumor immunity. Here, we report a tumor cell membrane-camouflaged nanoplatform (CM@HFeS/DOX/MSA-2) that couples ferroptosis amplification with cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway activation to overcome these barriers. The HFeS nanozyme promotes lipid peroxidation (LPO) and reactive oxygen species (ROS) generation, while …

Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies.

Molecular therapy. Oncology · 2026 · PMID 42519391

Bruton tyrosine kinase inhibitors (BTKis) have markedly improved the treatment landscape for B cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and Waldenström's macroglobulinemia, since the introduction of the first-in-class BTKi, ibrutinib, a decade ago. Despite their clinical success, the emergence of resistance to BTKis poses a significant therapeutic challenge. The mechanisms of resistance are multifactorial and include genetic mutations, activatio…

High affinity CD16v/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases.

Cytotherapy · 2026 · PMID 42475795

Allogeneic NK cell therapies offer a compelling alternative to T-cell based approaches for the treatment of autoimmune diseases, with advantages including potent effector function, a favorable safety profile, and off-the-shelf availability. AB-101 is a cord blood-derived, non-genetically modified, cryopreserved NK cell product manufactured at industrial scale using a 50L bioreactor process, yielding ≥110 billion cells per run. AB-101 expresses high levels of CD56 and CD16, including the high-affinity 158V/V variant…

Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma.

Computers in biology and medicine · 2026 · PMID 42235267

PURPOSE: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive subtype of non-Hodgkin lymphoma, characterized by clinical heterogeneity and chemoresistance. About 30% of patients relapse or develop refractory disease despite therapy. This study aimed to identify repurposed antitumor agents with potentially synergistic efficacy against DLBCL through an integrative in silico and in vitro approach. METHODS: DLBCL-associated genes were obtained from DisGeNET and GeneCards, and overlapping genes (OGs) …

Glyphosate-based herbicides induce oxidative stress: Insights from human biomarker and in vitro mutagenic studies.

Environmental toxicology and pharmacology · 2026 · PMID 42402262

Glyphosate-based herbicides (GBHs) are widely used and raise concerns about human health risks due to the detection of glyphosate (GLY) in body fluids. Their toxicity remains the subject of ongoing debate, especially regarding their carcinogenic potential, while epidemiological evidence associates GBHs exposure with increased non-Hodgkin lymphoma incidence. This study addresses key gaps by characterizing the kinetic profiles of GLY, its metabolites, and oxidative stress biomarkers in urine from 11 agricultural work…

Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.

Blood neoplasia · 2026 · PMID 42376204

Protein arginine methyltransferase 5 (PRMT5), a type II arginine methyltransferase, is overexpressed in several aggressive B-cell malignancies and facilitates cancer cell proliferation. JNJ-64619178, a selective small-molecule inhibitor targeting PRMT5, has previously shown promising preclinical activity across a range of hematological malignancies; however, the clinical activity of JNJ-64619178 monotherapy is limited despite strong target engagement. Therefore, we sought to identify rational combination partners f…

CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas.

Leukemia · 2026 · PMID 42362808

Circular RNAs (circRNAs) are increasingly recognized as functional non-coding transcripts with oncogenic potential. Here, a comprehensive analysis of circRNA expression in primary ALK(+) anaplastic large-cell lymphoma (ALK( + ) ALCL) is presented. Integrated transcriptomic profiling revealed that aberrant expression of circZBTB46 and of its linear host transcript, normally restricted to dendritic cells, is exclusive to ALK(+) lymphoma cells and driven by the oncogenic NPM1::ALK/STAT3 axis. Functional studies showed…

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.

The Lancet. Haematology · 2026 · PMID 42069410

BACKGROUND: The treatment landscape for relapsed or refractory diffuse large B-cell lymphoma has changed profoundly with the introduction of novel drug classes, some approved solely on the basis of single-arm early-phase trials. We aimed to evaluate antitumour activity and safety outcomes across drug classes in early-phase trials in relapsed or refractory diffuse large B-cell lymphoma since 2000. METHODS: We did a systematic review and meta-analysis of phase 1-2 trials. We searched PubMed, Embase.com, Web of Scienc…

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England) · 2026 · PMID 42134356

BACKGROUND: Adding ibrutinib to standard, first-line immunochemotherapy improves failure-free survival in adult patients aged 18-65 years with mantle cell lymphoma, according to the first results from the TRIANGLE trial. With prolonged follow-up, we investigated whether the addition of autologous stem-cell transplantation (ASCT) to an ibrutinib-containing regimen improves failure-free survival, and evaluated effects on overall survival. METHODS: We conducted a three-arm, randomised, open-label, phase 3 superiority …

Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.

International journal of clinical oncology · 2026 · PMID 41989666

BACKGROUND: This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma. METHODS: In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of ≥ grade 2 IRRs based on the National…

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology · 2026 · PMID 42285113

BACKGROUND: Anthracycline-free regimens are needed for older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We aim to evaluate the efficacy and safety of fixed-duration epcoritamab monotherapy versus epcoritamab with lenalidomide in this patient population. METHODS: This open-label, multicentre, randomised, phase 2 trial was conducted at 44 hospitals across 11 countries in Europe and Asia. Patients had newly diagnosed, histologically confirmed CD20-positive large B-cell lymphoma, were ineligible…

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology · 2026 · PMID 42283231

Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with …

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine · 2026 · PMID 42341302

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. METHODS: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) - autologous T cells expressing CD19-directed, 4-1BB-costimula…

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.

BMC cancer · 2026 · PMID 42581349

BACKGROUND: Brexucabtagene-autoleucel (brexu-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) product approved for relapsed/refractory Mantle Cell Lymphoma (MCL) after two prior treatment lines, including Bruton tyrosine kinase inhibitors (BTKi). Patients with high-risk (hr) disease-defined by high-intermediate or high-risk MIPI-c, p53 overexpression, or TP53 alterations-have a poor prognosis, underscoring the need for improved first-line strategies. The European Mantle Cell Lymphoma Network therefore …

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Blood · 2026 · PMID 42013019

Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and/or chimeric antigen receptor (CAR) T-cell therapy and those with high-risk features, have poor outcomes. The bispecific antibody, mosunetuzumab, combined with the antibody-drug conjugate (ADC), polatuzumab vedotin (Mosun-Pola), targets CD20 and CD79b via independent cell-killing mechanisms. In this multicenter phase 2 study, patients with MCL who had received ≥2 previous …

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.

American journal of hematology · 2026 · PMID 42305039

First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary end…

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Annals of hematology · 2026 · PMID 42209885

Peripheral T-cell lymphomas (PTCLs) are rare, aggressive malignancies with poor outcomes, particularly in the relapsed or refractory (R/R) setting. Given the frequent CD38 expression in PTCLs, this multicenter, open-label, single-arm phase II study (FIL_Dara-GDP; EudraCT 2018-002644-91) evaluated daratumumab, an anti-CD38 monoclonal antibody, combined with gemcitabine, dexamethasone, and cisplatin (D-GDP) in CD38-positive systemic PTCLs. The trial aimed to achieve a complete response (CR) rate of ≥ 40% after four c…

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

Oncoimmunology · 2026 · PMID 42415230

Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R2) for R/R FL. Epcoritamab + R2 pivotal data dem…

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42018969

PURPOSE: Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous, aggressive lymphomas. Five-year overall survival (OS) remains approximately 30%-40%, and most patients will develop relapsed or refractory (R/R) disease. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and PI3K-γ isoforms. Here, we report on the final analysis of the phase II PRIMO trial (ClinicalTrials.gov identifier: NCT03372057; Secura Bio, Inc) evaluating duvelisib monotherapy in R/R PTCL. METHODS: PRIMO was cond…

Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.

American journal of hematology · 2026 · PMID 41804087

In this single-arm, single-center, registrational phase 2 trial, tandem CD19/CD20 chimeric antigen receptor (CAR) T cell (TanCAR7) therapy showed promising efficacy and safety in patients with relapsed/refractory non-Hodgkin's lymphoma (r/r NHL). Here, we report 5-year follow-up results, including assessments of durable response, survival, and safety. We also investigated risk factors and biomarkers associated with treatment resistance or relapse and evaluated salvage therapies after CAR-T cell failure. Among 87 pa…

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

American journal of hematology · 2026 · PMID 41862428

Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (N = 94; median follow-up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 pri…

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.

Signal transduction and targeted therapy · 2026 · PMID 42036411

This phase 2, single-arm, multi-center study (NCT03934567) evaluates the efficacy and safety of abexinostat, a histone deacetylase inhibitor, in patients with relapsed or refractory (r/r) follicular lymphoma (FL). Eligible participants had previously received a minimum of two systemic treatment lines, such as cytotoxic agents and/or anti-CD20 monoclonal antibodies. Participants received abexinostat 80 mg oral twice daily on a schedule of seven days on and seven days off, within 28-day cycles, continuing until unacc…

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The Lancet. Haematology · 2026 · PMID 42660129

BACKGROUND: Chemotherapy-free regimens, such as rituximab and lenalidomide, are attractive first-line treatment options for follicular lymphoma, but combinations providing deeper, more durable responses are needed. We aimed to assess 3-year activity and safety of epcoritamab, a subcutaneously administered CD3 × CD20 bispecific antibody, plus rituximab-lenalidomide as first-line treatment for follicular lymphoma. METHODS: EPCORE NHL-2 is an open-label, phase 1b/2, clinical trial. Arm 6 of the study was conducted at …

Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

Nature communications · 2026 · PMID 42297808

Treatment options for relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) remain limited. In this phase 1b/2 trial (NCT05464433), we evaluated the safety and efficacy of liposomal mitoxantrone (Lipo-MIT) plus anti-PD-1 tislelizumab in this setting. During dose escalation, patients received Lipo-MIT (16 or 20 mg/m2) plus tislelizumab using a 3 + 3 design, followed by dose expansion at the recommended phase 2 dose (RP2D). The primary endpoint of the dose-escalation phase was dose-limiting tox…

An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42209393

INTRODUCTION: Management of relapsed mantle cell lymphoma (MCL) has included Bruton's tyrosine kinase (BTK) inhibitors for more than 10 years, but finding an optimal combination partner that meaningfully improves outcomes while limiting toxicity has been difficult. We conducted a phase 1/2 trial of ibrutinib and the proteasome inhibitor, ixazomib, in patients with relapsed/refractory MCL. PATIENTS AND METHODS: Patients and Methods: The primary endpoint for the phase 1 study was to determine the recommended phase 2 …

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Blood advances · 2026 · PMID 41544219

Marginal zone lymphoma (MZL) is a group of indolent B-cell malignancies with a remitting and relapsing course. For systemic disease, available first-line therapies include anti-CD20 antibody as monotherapy or in combination with chemotherapy (chemoimmunotherapy), with second-line options including covalent Bruton tyrosine kinase inhibitors (cBTKi). However, management of relapsed and refractory (R/R) MZL remains challenging. Pirtobrutinib, a highly selective, noncovalent BTKi has shown promising efficacy and tolera…

Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.

Nature communications · 2026 · PMID 42026073

Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at…

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology · 2026 · PMID 42393723

BACKGROUND: Failure after anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL) is associated with poor survival and there is no established standard of care. We previously reported the phase 2 LYSA BiCAR trial of short-ramp-up glofitamab after CAR T-cell failure. Here, we present the final survival results and a pre-specified external comparative effectiveness analysis against a contemporary control arm constructed from academic data. METHODS: BiCAR is a multicenter, sin…

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

Blood advances · 2026 · PMID 42160759

Extranodal natural killer/T-cell lymphoma (ENKTL) is rare, and treatment options for relapsed/refractory (R/R) disease are limited. This multicenter, single-arm phase 2 study evaluated the efficacy and safety of atezolizumab monotherapy in patients with R/R ENKTL. The primary end point was objective response rate (ORR), as assessed by an independent review committee (IRC). Fourteen patients were ultimately enrolled. Among the 13 with evaluable responses, the median age was 72 years (range, 27-80), 46% were female, …

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer · 2026 · PMID 42144261

BACKGROUND: Relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL) remains a major therapeutic challenge despite CD19-directed chimeric antigen receptor (CAR) T-cell therapies, with treatment failure often driven by antigen escape and limited CAR-T persistence. Dual targeting of CD19 and CD20 may mitigate antigen loss. We conducted an expanded phase I/II study of bispecific CD19/20 CAR-T cells and incorporated spatially resolved single-cell transcriptomics to evaluate tumor-intrinsic and microenvironmen…

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology · 2026 · PMID 42660131

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell non-Hodgkin lymphoma, but centralised manufacturing-with its complex logistics and long vein-to-vein times-drives up costs and restricts access. We aimed to evaluate the safety of GLPG5101, a fresh, CD19 CAR T-cell product manufactured through a decentralised process, and determine the recommended phase 2 dose. METHODS: This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study, was executed in…

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

Nature communications · 2026 · PMID 41986386

Despite the success of CAR T therapy in non-Hodgkin lymphoma (NHL), recurrence remains challenging. Previously, we showed that ex vivo priming with decitabine (DAC) enhances CAR T persistence and efficacy. Here, we report on an open-label non-randomised phase I/II trial (NCT04697940) evaluating DAC-primed CD19/CD20 dual-targeted CAR T cells (dCAR T) in 23 patients with relapsed or refractory NHL. Primary endpoints are safety and dose-toxicity for phase I, and overall response rate and complete response rate (CRR) f…

Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.

Transplantation and cellular therapy · 2026 · PMID 41525947

In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259

BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Hematological oncology · 2026 · PMID 42062177

The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). P…

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Endoscopic ultrasound (EUS) elastography-guided fine-needle aspiration cytology (FNAC) versus conventional EUS FNAC for solid pancreatic lesions: A pilot randomized trial.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025 · PMID 39230660

BACKGROUND: Endoscopic ultrasound guided fine-needle aspiration (EUS FNA) is the first-line modality to diagnose suspected solid pancreatic malignant lesions. Elastography-guided FNA has been shown to improve the diagnostic yield of EUS FNA but prospective studies are limited. The aim of the study was to compare diagnostic accuracy, sensitivity and specificity of conventional and elastography-guided EUS FNA in patients with suspected malignant pancreatic solid masses. METHODS: Patients with suspected malignant soli…

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41329901

PURPOSE: Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS: The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,48…

Vegetarian diets and cancer risk: pooled analysis of 1.8 million women and men in nine prospective studies on three continents.

British journal of cancer · 2026 · PMID 41748939

BACKGROUND: Vegetarian diets might influence cancer risk. METHODS: We studied 1,645,555 meat eaters, 57,016 poultry eaters, 42,910 pescatarians, 63,147 vegetarians and 8849 vegans in 9 cohorts (UK, US, Taiwan, India). After a median 16 years follow-up, incident cancers were: 4504 mouth and pharynx, 1308 oesophagus (squamous cell), 2105 oesophagus (adenocarcinoma), 3578 stomach, 30,528 colorectum, 2970 liver, 8030 pancreas, 3077 lung (never smokers), 61,368 breast, 11,220 endometrium, 8076 ovary, 45,946 prostate, 71…

RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.

American journal of hematology · 2026 · PMID 42124356

Relapsed/refractory (r/r) angioimmunoblastic T-cell lymphoma (AITL) is associated with a dismal prognosis, with historical overall survival (OS) < 6 months, underscoring the urgent need for novel therapies. We conducted the RCLARITY trial to evaluate the efficacy and safety of a chemotherapy-free regimen in this patient population. This single-arm, multicenter, prospective Phase II trial enrolled adult patients with r/r AITL. Patients received rituximab (375 mg/m2 intravenously on Day 1), lenalidomide (15 mg orally…

Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.

Nature communications · 2026 · PMID 42026073

Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at…

Serum triglyceride and apolipoprotein A1 as dynamic biomarkers in extranodal NK/T-cell lymphoma (ENKTL): A multicenter retrospective and prospective validation study.

Annals of hematology · 2025 · PMID 41242997

Extranodal NK/T-cell lymphoma (ENKTL), an aggressive non-Hodgkin lymphoma subtype, exhibits understudied links between lipid metabolism and clinical outcomes. We analyzed 1,017 patients newly diagnosed with ENKTL and matched controls, with longitudinal LC-MS-based metabolomic profiling (n = 29) and pretreatment tumor transcriptomic analysis (n = 65). Multivariable Cox models evaluated lipid biomarkers. Patients with ENKTL showed significantly elevated triglycerides (TG) and reduced apolipoprotein A1 (ApoA1) vs. con…

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665

BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42302353

BACKGROUND: Transformed indolent non-Hodgkin lymphoma (TiNHL) generally has poorer outcomes than de novo diffuse large B-cell lymphoma (dnDLBCL). Although anti-CD19 CAR T-cell therapy is standard for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), its prognostic role across histologies remains unclear. METHODS: We conducted a multicenter, retrospective/prospective observational study comparing R/R TiNHL and R/R dnDLBCL patients treated with commercial CAR T-cell therapy and enrolled in the Italian CART-SIE …

Baseline Risk of Treatment Abandonment and Survival of Children With Common and Curable Cancers in the Zero Abandonment Cash Transfer Programme-A Multi-Centre Prospective CANCaRe Africa Study.

Pediatric blood & cancer · 2026 · PMID 42578510

BACKGROUND: The WHO Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common and curable cancers. This study assessed the risk of treatment abandonment (TxA) and the impact on survival of five of these cancers in sub-Saharan Africa in preparation for a cash transfer intervention. METHODS: This multi-centre, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphobla…

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances · 2026 · PMID 41979332

Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 c…

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

MedScience · 2026 · PMID 42228038

This study evaluated the efficacy and safety of obinutuzumab plus bendamustine (GB) as first-line treatment for indolent B-cell lymphomas. In this prospective, multicenter, single-arm trial (NCT06415708), adults with newly diagnosed indolent B-cell lymphomas-including follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), hairy cell leukemia variant (HCL-v), and unclassified B-cell lymphoproliferative disorder (BCLPD-U)-received six induction cycles of GB followed by 2 years of …

Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study.

Journal of neuro-oncology · 2026 · PMID 42667447

BACKGROUND: Primary Large-B-Cell Lymphoma of the CNS (PCNS-LBCL) is a rare, aggressive tumor often sensitive to corticosteroid therapy (CST). This multicenter study investigated the spectrum of radiological responses to routine CST and evaluated its impact on patient prognosis. METHODS: The researchers utilized a prospective cohort of 18 patients for volumetric MRI analysis and a combined prospective-retrospective cohort of 31 patients for 2D tumor analysis. Patients received CST post-biopsy, with follow-up MRIs pe…

De Novo Cancer in Liver Transplant Patients With HIV Infection: A Multicenter Nationwide Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · PMID 41989878

BACKGROUND: Patients with human immunodeficiency virus (HIV) infection have been gradually accepted as solid organ transplant recipients, although there is still concern that the burden of immunosuppression and HIV infection could increase the risk of post-transplant cancer. METHODS: The risk of de novo cancer was evaluated in a prospective cohort of 272 HIV-positive and 816 matched HIV-negative liver transplant recipients in Spain (2002-2012). All tumors, except hepatocellular carcinoma recurrence and non-melanoma…

Residential proximity to dioxin-emitting facilities and risk of non-Hodgkin lymphoma in the NIH-AARP Diet and Health Study.

Environment international · 2024 · PMID 38795658

BACKGROUND: Polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) are persistent organic pollutants emitted from industrial sources. Residential proximity to these emissions has been associated with risk of non-Hodgkin lymphoma (NHL) in a limited number of studies. METHODS: We evaluated associations between residential proximity to PCDD/F-emitting facilities and NHL in the NIH-AARP Diet and Health Study (N = 451,410), a prospective cohort enrolled in 1995-1996 in 6 states and 2 U.S. cities. We linked enroll…

Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.

Leukemia · 2026 · PMID 41981103

Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an elevated risk of hematologic and solid cancers. We performed a prospective cohort study, including 63690 patients with a first diagnosis of primary cancer in the UK Biobank during 2006 to 2022, to investigate the association of pre-diagnostic CHIP with future risk of second cancers. Cox regression was employed to assess the association between pre-diagnostic CHIP and risk of developing second cancer among patients with primary cancer. We i…

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

The Lancet. Haematology · 2026 · PMID 42285114

BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise in treating patients with haematological malignancies. We aimed to investigate short-term patient-reported symptomatic adverse events in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy and compare them with those reported by their treating physicians. We also examined factors predicting overall short-term burden of therapy. METHODS: This was a prospective, observational, multicentre study enrolling patients…

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41645921

BACKGROUND: The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: 'SKIN disease profiling by an Exploratory, pRospective, biomarker study …

Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41428995

PURPOSE: Circulating tumor DNA (ctDNA) is emerging as a promising tool to monitor treatment response in large B-cell lymphoma (LBCL). Tracking tumor-specific phased variants (PVs) allows ultrasensitive detection of minimal residual disease (MRD) that may enhance the accuracy of response assessment. Previous studies have been constrained by small cohort size, retrospective design, or assays limited to a single commercial provider. PATIENTS AND METHODS: DIRECT was a prospective, multisite study evaluating the utility…

Vulnerability to Infections and Secondary Immunodeficiencies in Patients with Non-Hodgkin's Lymphomas Starting Anti-CD20 Antibody-Containing Therapies.

Oncology research and treatment · 2026 · PMID 41697935

INTRODUCTION: Only limited data exist about immune status, secondary immunodeficiencies, and vulnerability to infections in correlation to anti-CD20 antibody-containing therapies (CD20CT) in non-Hodgkin's lymphoma (NHL) patients. Morbidity, mortality, and hospitalisation rates in routine care are not known. METHODS: Multicentre prospective observational study of 101 unselected NHL patients who were about to start CD20CT between April, 2021 and December, 2023 in nine haematology/oncology group practices in Germany. …

Reduced-dose Radiation Therapy for Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Multi-Institutional Prospective Study (KROG 16-18).

International journal of radiation oncology, biology, physics · 2025 · PMID 39448038

PURPOSE: Definitive radiation therapy (RT) of 30 Gy or higher is commonly recommended to treat Helicobacter pylori-independent gastric mucosa-associated lymphoid tissue (MALT) lymphoma with an excellent disease control rate. However, the efficacy of reduced-dose RT has not yet been evaluated in a prospective cohort study. This multi-institutional study aimed to determine the role of reduced-dose RT in the treatment of stage IE gastric MALT lymphoma. METHODS AND MATERIALS: Between March 2017 and June 2022, 62 patien…

Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.

Breast (Edinburgh, Scotland) · 2026 · PMID 42090861

BACKGROUND: The true incidence of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare cancer associated with textured breast implants, remains uncertain due to limitations of implant exposure data and long-term follow-up. Concerns regarding other implant-associated malignancies are growing. This study aimed to determine the incidence of BIA-ALCL, non-BIA-ALCL lymphoma, and Breast Implant Associated-Squamous Cell Carcinoma (BIA-SCC). METHODS: 10,339 women with a first-time breast implantation…

Understanding the factors influencing quality of life among survivors of Non-Hodgkin lymphoma after completing primary treatment: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 41774244

PURPOSE: To evaluate and synthesize the existing evidence on factors influencing the quality of life (QoL) of non-Hodgkin lymphoma (NHL) survivors and the impact of these factors on their QoL. METHODS: A systematic review was conducted following PRISMA guidelines, with searches in CINAHL, MEDLINE, PubMed, ScienceDirect, Scopus, and Web of Science. Studies published between 2014 and 2025 were included if they were original English-language research involving adult (age ≥ 18 years) NHL survivors and focused on factor…

Effects of physical activity and exercise interventions in health-related variables in Hodgkin's and non-Hodgkin's lymphoma patients during clinical treatment: a systematic review and single-arm meta-analysis.

The Journal of sports medicine and physical fitness · 2026 · PMID 41757629

INTRODUCTION: Cancer-related fatigue and reduced health-related quality of life (HRQOL) are common among lymphoma patients undergoing treatment. Exercise may be safe and feasible for individuals with hematological malignancies, with potential benefits in mitigating treatment-related toxicity and enhancing treatment tolerance. This systematic review and meta-analysis aimed to evaluate the effects of exercise interventions on health-related outcomes such as HRQOL, muscle strength, cardiorespiratory fitness (CRF), fat…

Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.

Blood advances · 2026 · PMID 41351516

The incidence of diffuse large B-cell lymphoma (DLBCL) increases with older age. Thus, subgroup reporting for older adults in clinical trials is necessary to determine the relevance of novel therapy outcomes to this vulnerable population. This study assessed subgroup reporting of older adults (aged ≥65 years) enrolled in US Food and Drug Administration and European Medicines Agency registration trials for DLBCL between 2017 and 2023. Clinical efficacy end points for each trial were extracted from ClinicalTrials.gov…

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials.

BMJ open · 2026 · PMID 41651511

INTRODUCTION: Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that primarily affects the skin and can mimic inflammatory dermatoses. Unlike many skin diseases, CTCL can lead to disabling symptoms, and advanced CTCL can even be fatal. Early studies investigating health-related quality of life (HRQOL) in patients with mycosis fungoides (MF) and Sézary syndrome (SS), common subtypes of CTCL, demonstrated significant impairment across numerous domains. The aim of this current study is to develop a …

Cost-utility Analysis of R-CHOP vs CHOP in Patients with Non-Hodgkin's Lymphoma: A Systematic Review.

Acta medica Philippina · 2026 · PMID 41835908

BACKGROUND AND OBJECTIVES: Non-Hodgkin Lymphoma (NHL) ranks 11th in cancer incidence and mortality in the Philippines with the combination chemotherapy composed of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) being commonly used as treatment. However, the addition of Rituximab to CHOP (R-CHOP) has been shown to exhibit higher response rates and longer remissions, potentially improving quality of life. Currently, there is conflicting evidence on the cost-utility of CHOP versus R-CHOP. The study …

Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.

Journal of patient-reported outcomes · 2026 · PMID 42329537

INTRODUCTION: Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL): measures of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Symptoms, Mantle Cell Lymphoma (MCL) Symptoms, and an Expanded Fatigue measure. The objective of this study was to assess ps…

A Parent-Delivered Foot Bath Intervention for Chemotherapy-Related Fatigue in Children with Cancer: A Family-Centered Randomized Controlled Trial.

Children (Basel, Switzerland) · 2026 · PMID 42509946

Background/Objectives: Chemotherapy-related fatigue (CRF) affects 50-80% of children receiving chemotherapy and significantly impairs quality of life. Despite the family-centered care framework guiding pediatric oncology practice, evidence on parent-delivered, home-based non-pharmacological interventions for CRF remains limited. This study aimed to evaluate the effect of a parent-delivered warm-water foot bath on CRF in children aged 7-12 years undergoing chemotherapy. Methods: A two-arm parallel randomized control…

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.

BMC cancer · 2026 · PMID 42581349

BACKGROUND: Brexucabtagene-autoleucel (brexu-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) product approved for relapsed/refractory Mantle Cell Lymphoma (MCL) after two prior treatment lines, including Bruton tyrosine kinase inhibitors (BTKi). Patients with high-risk (hr) disease-defined by high-intermediate or high-risk MIPI-c, p53 overexpression, or TP53 alterations-have a poor prognosis, underscoring the need for improved first-line strategies. The European Mantle Cell Lymphoma Network therefore …

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review.

Journal of patient-reported outcomes · 2026 · PMID 41606262

BACKGROUND: Non-Hodgkin lymphoma (NHL) constitutes a biologically and clinically heterogeneous group of lymphoid malignancies, with varying prognoses and treatment aims between indolent and aggressive subtypes. While survival outcomes remain key efficacy measures, they insufficiently capture the impact of disease and treatment on daily physical and psychosocial functioning, as well as quality of life (QoL). OBJECTIVES: To characterize the use and reporting of patient-reported outcomes (PROs) in adult NHL randomized…

Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Blood advances · 2026 · PMID 41512176

The phase 2 ALYCANTE trial aimed to evaluate the investigator-assessed complete metabolic response at 3 months from the axicabtagene ciloleucel (axi-cel) infusion as a primary end point in patients with high-risk relapsed/refractory large B-cell lymphoma who are ineligible for autologous stem cell transplantation (ASCT). This study showed a significant improvement in complete metabolic response rate at 3 months based on historical controls. This study reports the health-related quality of life (HRQoL) results as a …

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665

BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…

Age-related histopathological and immunophenotypic variations in early-stage mycosis fungoides: a multicentre retrospective study in Türkiye.

BMJ open · 2026 · PMID 41985965

OBJECTIVES: Early-stage mycosis fungoides (MF) is diagnostically challenging due to overlap with inflammatory dermatoses. Age-related immunological and cutaneous changes may modify histopathological presentation. We aimed to compare clinical, histopathological and immunophenotypic features of early-stage MF between geriatric and non-geriatric patients. DESIGN: Multicentre retrospective cross-sectional study. SETTING: Dermatology departments of tertiary centres in Türkiye. PARTICIPANTS: A total of 541 patients diagn…

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

The Lancet. Haematology · 2026 · PMID 42285114

BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise in treating patients with haematological malignancies. We aimed to investigate short-term patient-reported symptomatic adverse events in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy and compare them with those reported by their treating physicians. We also examined factors predicting overall short-term burden of therapy. METHODS: This was a prospective, observational, multicentre study enrolling patients…

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41645921

BACKGROUND: The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: 'SKIN disease profiling by an Exploratory, pRospective, biomarker study …

Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index in Patients With Lymphoma.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026 · PMID 42002076

OBJECTIVES: To further evaluate the psychometric properties of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18), including estimates of meaningful within-patient change thresholds, to support its ability to reliably and validly measure clinical- and patient-relevant outcomes in diverse research settings. METHODS: Data from a longitudinal multicenter clinical trial in patients with indolent B cell lymphoma and a single-institution observational …

Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome.

Acta dermato-venereologica · 2026 · PMID 42454691

Mycosis fungoides (MF) and Sézary syndrome (SS) are rare cutaneous lymphomas with limited data on psychological burden. This observational, cross sectional questionnaire study assessed symptom burden, psychological distress and quality of life (QoL) in patients with MF and SS in Western Sweden and compared outcomes with psoriasis. Sixty patients were included, 80% with early-stage disease. Most reported minimal depression, anxiety and QoL impairment. Moderate-to-severe depression occurred in 36% of advanced disease…

Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades.

Journal of cancer survivorship : research and practice · 2025 · PMID 37938431

PURPOSE: The impact of changes in therapy for childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) on the prevalence of physical performance limitations and participation restrictions among survivors is unknown. We aimed to describe the prevalence of reduced function among ALL and NHL survivors by treatment era. METHODS: Participants included survivors of childhood ALL and NHL, and a cohort of their siblings, participating in the Childhood Cancer Survivor Study (CCSS). Physical function was m…

Pre-Pectoral Breast Reconstruction after Mastectomy: Current Evidence, Knowledge Gaps, and Rationale for the I-PREPARE EUBREAST-11R Trial.

Breast care (Basel, Switzerland) · 2026 · PMID 42383235

INTRODUCTION: Pre-pectoral implant-based breast reconstruction (IBR) has emerged as a promising alternative to conventional subpectoral approaches following nipple- or skin-sparing mastectomy. However, long-term oncological safety, complication profiles, and outcomes in specific subgroups, such as patients receiving radiation therapy (RT), remain under investigation. Contemporary evidence is mainly derived from retrospective studies with limited follow-up, reporting heterogeneous results. The I-PREPARE trial (EUBRE…

Further validation of the patient roles and responsibilities scale.

Health psychology and behavioral medicine · 2026 · PMID 42549295

BACKGROUND: The Patient Roles and Responsibilities Scale (PRRS) measures the impact of cancer and treatment on 'real world' functioning such as caregiving and financial responsibilities. It was developed and validated in advanced cancer but with the intention to be sufficiently generic and appropriate for use in all cancers and stages. Here we further investigate the psychometric performance of the PPRS when completed by people three years after cancer diagnosis, treated with curative intent. METHODS: This is a sec…

Exploratory association of muscle and adipose tissue indices with clinical outcomes in aggressive lymphomas.

Cancer · 2026 · PMID 41669999

BACKGROUND: Muscle and adipose tissue quantified on computed tomography (CT) are associated with overall survival (OS), toxicity, and quality of life (QOL) in solid tumor malignancies. This study sought to evaluate the association of body composition with outcomes in older adult aggressive non-Hodgkin lymphoma (aNHL). METHODS: The authors conducted a longitudinal study of 105 adults ≥65 years old with aNHL receiving chemoimmunotherapy. They performed body composition analysis on pretreatment CTs (third lumbar verte…

The course of self-perceived cognitive functioning among patients with lymphoma and the co-occurrence with fatigue and psychological distress.

Journal of cancer survivorship : research and practice · 2025 · PMID 37755680

PURPOSE: To investigate the proportion of patients with lymphoma with persistent clinically relevant cognitive impairment, and its relation to treatment, fatigue, and psychological distress. METHODS: Patients with diffuse-large-B-cell-lymphoma (DLBCL), follicular-lymphoma (FL), and chronic-lymphocytic-leukemia (CLL)/small-lymphocytic-lymphoma (SLL), diagnosed between 2004-2010 or 2015-2019, were followed up to 8 years post-diagnosis. Sociodemographic and clinical data were obtained from the Netherlands Cancer Regis…

Low musculoskeletal health literacy is associated with inferior outcomes in total shoulder arthroplasty.

JSES international · 2026 · PMID 42063489

BACKGROUND: The aim of this study was to investigate the impact of musculoskeletal (MSK) health literacy on clinical outcomes and patient satisfaction following total shoulder arthroplasty (TSA). We hypothesized that low MSK health literacy score would be associated with inferior clinical outcomes and lower patient satisfaction rates. METHODS: A retrospective cohort study was conducted at a tertiary care center. Patients between 6 months and 9 years post-operative following shoulder arthroplasty, both anatomic tota…

Longitudinal Patient-Reported Symptom Change Patterns and Prediction of Future Health-Related Quality of Life in Childhood Cancer Survivors: A Machine Learning Approach from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.

Cancers · 2026 · PMID 42192908

BACKGROUND: Adult survivors of childhood cancer face a significant risk for treatment-related late effects that may impair health-related quality of life (HRQoL). Incorporating longitudinal changes in patient-reported symptoms beyond treatment-based risk factors may enhance the prediction of HRQoL. METHODS: Survivors (n = 576) dually enrolled in the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study reported 37 symptoms across 10 domains at three time points over 20 years to ascertain longitudinal s…

Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population.

Journal of medical economics · 2026 · PMID 41705966

AIM: Conventional therapies in Japan for relapsed or refractory large B-cell lymphoma (r/r LBCL) require intravenous infusion (IV), while epcoritamab is administered subcutaneously. Despite the expected quality of life (QOL) improvement from reduced drug administration burden, limited data exists on QOL for common r/r LBCL treatment modalities. This study aimed to estimate the impact of drug administration on QOL (i.e. process utility) across treatments for r/r LBCL using responses from the Japanese general populat…

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.

Blood cancer journal · 2026 · PMID 42362499

Pola-R-CHP regimen is the new standard of care for untreated diffuse large B-cell lymphoma (DLBCL) patients, following the POLARIX trial. This study evaluates whether clinical trial (RCT) efficacy and safety are reproducible in real-world evidence (RWE) settings. This systematic review and meta-analysis compared outcomes between RCTs and RWE studies. Primary endpoints were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Meta-regression explored heterogeneity using age, Inter…

Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.

Acta neurologica Belgica · 2026 · PMID 41212511

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…

Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.

The Lancet. Haematology · 2026 · PMID 41448213

BACKGROUND: The optimal treatment sequence for large B-cell lymphoma is unknown. We aimed to assess through meta-analysis the comparative effectiveness of bispecific antibodies (BsAb) after chimeric antigen receptor T-cell therapy (CAR-T) or CAR-T after BsAb. METHODS: We performed a systematic review and meta-analysis by searching MEDLINE and Embase from Jan 1, 2010, until Sept 16, 2025, and haematological conferences in 2024 and 2025 for studies assessing effectiveness of BsAb monotherapy or combination therapy af…

CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.

La Clinica terapeutica · 2026 · PMID 42340791

BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…

Progression-free survival is strongly associated with overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era.

Journal of cancer policy · 2026 · PMID 41429401

INTRODUCTION: In clinical trials for diffuse large B-cell lymphoma (DLBCL), progression-free survival (PFS) has been used as a validated surrogate endpoint to help expedite drug development and regulatory approval. The advent of chimeric antigen receptor (CAR) T-cell therapies has radically changed the treatment landscape, potentially prolonging post-progression survival and weakening the correlation between PFS and overall survival (OS). This study evaluates the utility of PFS as a surrogate endpoint for OS in rel…

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation · 2026 · PMID 42332219

Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. This systematic review evaluates the safety, efficacy, and feasibility of bendamustine-based LD in patients undergoing CAR-T therapy for hematologic malignancies. A comprehensive literature …

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.

Cancer · 2026 · PMID 41701615

BACKGROUND: CD19-directed chimeric antigen receptor (CAR)-T-cell therapy has emerged as a second-line option for relapsed/refractory large B-cell lymphoma (R/R LBCL). However, its long-term benefits over standard of care (SOC) remain a matter of debate. METHODS: A systematic review and meta-analysis was performed of three randomized controlled trials (ZUMA-7, TRANSFORM, BELINDA) and one real-world comparative study evaluating second-line CAR-T versus standard-of-care chemoimmunotherapy (±autologous stem cell transp…

Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525

Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259

BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Hematological oncology · 2026 · PMID 42062177

The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). P…

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.

Blood · 2026 · PMID 41347825

We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 …

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England) · 2026 · PMID 42217458

BACKGROUND: Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. METHODS: frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 29…

Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Systematic reviews · 2026 · PMID 42244006

BACKGROUND: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a therapeutic challenge, particularly for patients ineligible for stem-cell transplantation or CAR T-cell therapy. Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, has demonstrated promising single-agent activity in recent studies and is approved in this setting. In this meta-analysis, we aim to assess the efficacy and safety of loncastuximab tesirine monotherapy in patients with R/R DLBCL. METHODS: A systematic review…

Antibody-drug conjugate development in lymphoma: a systematic clinical trial landscape analysis.

Frontiers in immunology · 2026 · PMID 42620849

INTRODUCTION: Antibody-drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate development trends, evidence maturity, molecular architecture, combination strategies, inactive development, and safety reporting. METHODS: We searched Trialtrove for Phase I-IV interventional trials evaluating at least one ADC in lymphoma, with actual or anticipated star…

Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma.

Current research in translational medicine · 2026 · PMID 42184607

No recognized standard of care exists at the present time for treatment for large B-cell non-Hodgkin lymphoma that relapses or progresses after chimeric antigen receptor T-cell (CAR T-cell) therapy. Bispecific T-cell engagers (BiTEs) have emerged as an effective treatment for patients with relapsed or refractory (R/R) LBCL. The purpose of this systematic review and meta-analysis is to appraise the totality of evidence on the role of BiTEs as treatment for LBCL after CAR T-cell therapy failure. Results showed that p…

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England) · 2026 · PMID 42134356

BACKGROUND: Adding ibrutinib to standard, first-line immunochemotherapy improves failure-free survival in adult patients aged 18-65 years with mantle cell lymphoma, according to the first results from the TRIANGLE trial. With prolonged follow-up, we investigated whether the addition of autologous stem-cell transplantation (ASCT) to an ibrutinib-containing regimen improves failure-free survival, and evaluated effects on overall survival. METHODS: We conducted a three-arm, randomised, open-label, phase 3 superiority …

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

British journal of haematology · 2026 · PMID 42304704

Early identification of patients at risk of failing first-line therapy remains a key challenge in primary mediastinal B-cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL. Baseline PET/computed tomography (CT) scans from 501 patients enrolled in the International Extranodal Lymphoma Study Group 37 (IELSG37) trial and treated with rituximab- and doxorubicin-based immunochemotherapy were analysed. Functional PET parameters reflecti…

Mecapegfilgrastim for Prophylaxis of Immunochemotherapy-Induced Neutropenia in Patients With Diffuse Large B-Cell Lymphoma: A Multicenter Pilot Trial.

Cancer medicine · 2026 · PMID 42030265

BACKGROUND: This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy-induced neutropenia in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL). METHODS: In this open-label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no prophylaxis. All participants received 4 cycles of R-CHOP or R-CHOP-like regimens. The primary endpoint was the incidence of grade ≥ 3 neutropenia during cycle 1. RESULTS: Between O…

Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.

International journal of clinical oncology · 2026 · PMID 41989666

BACKGROUND: This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma. METHODS: In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of ≥ grade 2 IRRs based on the National…

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Hepatology communications · 2025 · PMID 41335575

BACKGROUND AND AIMS: Immunosuppression can cause hepatitis B virus (HBV) reactivation, leading to severe outcomes in patients with "resolved" HBV infection. This multicenter, randomized, placebo-controlled trial assessed the efficacy of preemptive antiviral therapy in HBsAg-negative, anti-HBc-positive patients receiving rituximab-based chemotherapy for non-Hodgkin lymphoma (NHL). METHODS: Patients were randomized 1:1 to tenofovir alafenamide (TAF)/placebo across 3 phases: chemotherapy plus TAF/placebo (phase 1), TA…

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology · 2026 · PMID 42285113

BACKGROUND: Anthracycline-free regimens are needed for older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We aim to evaluate the efficacy and safety of fixed-duration epcoritamab monotherapy versus epcoritamab with lenalidomide in this patient population. METHODS: This open-label, multicentre, randomised, phase 2 trial was conducted at 44 hospitals across 11 countries in Europe and Asia. Patients had newly diagnosed, histologically confirmed CD20-positive large B-cell lymphoma, were ineligible…

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.

PloS one · 2024 · PMID 39088571

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma subtype with a significant relapse rate and poor prognosis in relapsed/refractory (R/R) patients. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) has demonstrated promising efficacy and safety as salvage therapy for R/R DLBCL. This systematic review protocol aims to comprehensively evaluate the efficacy of Pola-BR for the treatment of R/R DLBCL by synthesizing data from relevant randomized controlled…

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood · 2026 · PMID 41915772

In the multinational, phase 3 RELEVANCE trial, 1030 patients with previously untreated follicular lymphoma were randomized to receive rituximab + lenalidomide (R2; n = 513) or rituximab-based immunochemotherapy (R-Chemo; n = 517). In the final analysis, at 120 months of follow-up, median progression-free survival (PFS) was comparable between the treatment groups: 110.6 months with R2 vs 102.8 months with R-Chemo, according to the independent review committee assessment. The 10-year PFS rates were 46.4% for R2 and 4…

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Lancet (London, England) · 2026 · PMID 41371238

BACKGROUND: An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R2 versus R2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy. METHODS: In this multicountry, open-label, phase 3 trial, participants were…

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026 · PMID 42323047

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next…

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology · 2026 · PMID 42313425

IMPORTANCE: T-cell-engaging bispecific antibodies (BsAbs) are increasingly used in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). As these agents transition into earlier courses of therapy and broader clinical use, understanding their safety profile is critical. While second primary malignant neoplasms (SPMs) represent a key long-term safety signal, small sample sizes, single-arm trials, short follow-up, and heterogeneous reporting have limited reliable estimation of their frequency. OBJECTIVE: To est…

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.

Journal of cellular and molecular medicine · 2026 · PMID 42687221

Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment-naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta-analysis was intended to evaluate their efficacy, addressing critical gaps in clinical decision-making. We systematically searched PubMed, Embase, and Cochrane up to January 2025 for studies (RCT/single-arm) assessing the efficacy of BTKis in MCL pa…

Pesticide exposure and all health outcomes: An umbrella review of meta-analyses of observational studies.

Journal of hazardous materials · 2026 · PMID 42485730

Although pesticide exposure occurs through multiple pathways and has been linked to diverse health outcomes, the overall evidence remains unclear. We systematically searched PubMed/MEDLINE, Embase, CINAHL, and Google Scholar up to November 20, 2025, for meta-analyses examining pesticide exposure and adverse health outcomes. We recalculated pooled estimates using random-effects models and converted all effect metrics to equivalent odds ratios with 95% confidence intervals. The quality of included reviews was assesse…

Antibody-drug conjugate development in lymphoma: a systematic clinical trial landscape analysis.

Frontiers in immunology · 2026 · PMID 42620849

INTRODUCTION: Antibody-drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate development trends, evidence maturity, molecular architecture, combination strategies, inactive development, and safety reporting. METHODS: We searched Trialtrove for Phase I-IV interventional trials evaluating at least one ADC in lymphoma, with actual or anticipated star…

Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis.

Frontiers in veterinary science · 2026 · PMID 42656497

BACKGROUND: Canine lymphoma (cL), the second most common canine cancer after mammary carcinoma, presents therapeutic challenges due to limitations of conventional regimens, necessitating novel therapeutic approaches. Tyrosine kinase inhibitors (TKIs), which have demonstrated efficacy in human non-Hodgkin lymphoma (NHL), are increasingly being investigated as targeted therapies for cL, which also serves as a valuable translational model for NHL research. OBJECTIVES: To systematically evaluate the efficacy of TKIs in…

Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review.

Frontiers in immunology · 2026 · PMID 42643454

BACKGROUND: Hematologic neoplasms remain a growing global burden, with relapse, resistance, and limited treatment options persisting. Bispecific antibodies (BsAbs) offer a novel multi-antigen targeting strategy. This systematic review assesses their efficacy and safety, offering an in-depth appraisal of their therapeutic potential and the unmet medical needs. METHODS: We conducted this systematic review following the PRISMA 2020 guidelines. Articles published up to 20 June 2026 were searched across PubMed, Scopus, …

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Lancet (London, England) · 2026 · PMID 41371238

BACKGROUND: An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R2 versus R2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy. METHODS: In this multicountry, open-label, phase 3 trial, participants were…

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42407012

PURPOSE: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatment options. We evaluated the efficacy and safety of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) as an alternative therapy in patients with transplant-ineligible R/R DLBCL. METHODS: The phase III POLARGO trial was a randomized, open-label, global study. Following a Pola-R-GemOx safe…

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology · 2026 · PMID 42283231

Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with …

Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.

Haematologica · 2025 · PMID 40207715

The multi-center randomized phase III NHL-004 study compared etoposide, dexamethasone and pegaspargase (ESA) versus the methotrexate, etoposide, dexamethasone and pegaspargase (MESA) regimen, combined with sandwiched radiotherapy, in newly diagnosed early-stage nasal natural killer / T-cell lymphoma (NKTCL). Here we report the long-term outcomes (median follow-up, 64 months) and biomarker analysis. A total of 256 eligible patients aged 14-70 years were randomly assigned (1:1) to the ESA or the MESA arm. The 5-year …

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Blood advances · 2026 · PMID 42269085

In the phase 3 STARGLO trial, glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) demonstrated superior overall survival (OS) vs rituximab plus GemOx (R-GemOx), in patients with autologous stem cell transplant (ASCT)-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We present efficacy and safety from STARGLO, with 3 years of follow-up, including in clinically relevant subgroups. After a median OS follow-up of 35.1 months (data cutoff: 1 May 2025), Glofit-GemOx continued to demonstrate …

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.

BMC cancer · 2026 · PMID 42581349

BACKGROUND: Brexucabtagene-autoleucel (brexu-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) product approved for relapsed/refractory Mantle Cell Lymphoma (MCL) after two prior treatment lines, including Bruton tyrosine kinase inhibitors (BTKi). Patients with high-risk (hr) disease-defined by high-intermediate or high-risk MIPI-c, p53 overexpression, or TP53 alterations-have a poor prognosis, underscoring the need for improved first-line strategies. The European Mantle Cell Lymphoma Network therefore …

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.

British journal of haematology · 2026 · PMID 42669887

The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ibrutinib (560 mg daily for 24 months, arm B) in patients with advanced follicular lymphoma in need of systemic therapy. The primary end-point, complete remission (CR) rate at 24 …

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.

American journal of hematology · 2026 · PMID 42305039

First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary end…

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Blood · 2026 · PMID 42013019

Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and/or chimeric antigen receptor (CAR) T-cell therapy and those with high-risk features, have poor outcomes. The bispecific antibody, mosunetuzumab, combined with the antibody-drug conjugate (ADC), polatuzumab vedotin (Mosun-Pola), targets CD20 and CD79b via independent cell-killing mechanisms. In this multicenter phase 2 study, patients with MCL who had received ≥2 previous …

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

Oncoimmunology · 2026 · PMID 42415230

Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R2) for R/R FL. Epcoritamab + R2 pivotal data dem…

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The Lancet. Haematology · 2026 · PMID 42660129

BACKGROUND: Chemotherapy-free regimens, such as rituximab and lenalidomide, are attractive first-line treatment options for follicular lymphoma, but combinations providing deeper, more durable responses are needed. We aimed to assess 3-year activity and safety of epcoritamab, a subcutaneously administered CD3 × CD20 bispecific antibody, plus rituximab-lenalidomide as first-line treatment for follicular lymphoma. METHODS: EPCORE NHL-2 is an open-label, phase 1b/2, clinical trial. Arm 6 of the study was conducted at …

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

Blood advances · 2026 · PMID 42160759

Extranodal natural killer/T-cell lymphoma (ENKTL) is rare, and treatment options for relapsed/refractory (R/R) disease are limited. This multicenter, single-arm phase 2 study evaluated the efficacy and safety of atezolizumab monotherapy in patients with R/R ENKTL. The primary end point was objective response rate (ORR), as assessed by an independent review committee (IRC). Fourteen patients were ultimately enrolled. Among the 13 with evaluable responses, the median age was 72 years (range, 27-80), 46% were female, …

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology · 2026 · PMID 42660131

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell non-Hodgkin lymphoma, but centralised manufacturing-with its complex logistics and long vein-to-vein times-drives up costs and restricts access. We aimed to evaluate the safety of GLPG5101, a fresh, CD19 CAR T-cell product manufactured through a decentralised process, and determine the recommended phase 2 dose. METHODS: This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study, was executed in…

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42274647

PURPOSE: In large B-cell lymphoma (LBCL), use of high-dose methotrexate (HD-MTX) to prevent CNS relapse (so-called CNS prophylaxis) remains controversial. International guidelines continue to recommend HD-MTX in patients deemed ultra high risk (UHR) because of a lack of robust data specific to these subgroups. This study was designed to examine the impact of HD-MTX specifically in UHR patients. METHODS: Data from two previous retrospective analyses were combined to produce a cohort of UHR patients (≥1 of the follow…

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42385124

PURPOSE: Mantle cell lymphoma (MCL) is a rare and typically aggressive B-cell non-Hodgkin lymphoma characterized by recurrent relapse after short remissions. Sonrotoclax (BGB-11417) is a next-generation B-cell lymphoma 2 inhibitor with greater selectivity and potency than venetoclax, a shorter half-life, and no drug accumulation. Sonrotoclax monotherapy was evaluated in Bruton tyrosine kinase inhibitor-pretreated patients with relapsed/refractory (R/R) MCL. METHODS: BGB-11417-201 (ClinicalTrials.gov identifier: NCT…

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42302353

BACKGROUND: Transformed indolent non-Hodgkin lymphoma (TiNHL) generally has poorer outcomes than de novo diffuse large B-cell lymphoma (dnDLBCL). Although anti-CD19 CAR T-cell therapy is standard for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), its prognostic role across histologies remains unclear. METHODS: We conducted a multicenter, retrospective/prospective observational study comparing R/R TiNHL and R/R dnDLBCL patients treated with commercial CAR T-cell therapy and enrolled in the Italian CART-SIE …

CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.

Haematologica · 2025 · PMID 40438977

Chimeric antigen receptor (CAR) T expansion has been linked to anti-tumor response in relapsed/refractory large B-cell lymphoma both in clinical trials and smaller real-world studies. Here, we present the largest multicenter real-world analysis to date, evaluating 262 patients treated with tisagenlecleucel or axicabtagene ciloleucel in second or subsequent relapse. Our findings underscore the complementary roles of multiparameter flow cytometry and droplet digital polymerase chain reaction in monitoring CAR T cells…

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259

BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…

Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.

Annals of hematology · 2025 · PMID 40397196

When different therapies provide similar cure rates, health-related quality of life (HRQoL) may become crucial for the choice of treatment. In the Positron Emission Tomography-guided Therapy of Aggressive non-Hodgkin Lymphomas (PETAL) trial, we compared six cycles of R-CHOP with or without two extra doses of rituximab in prognostically favorable interim PET (iPET)-negative patients, while eight cycles of R-CHOP were compared with two R-CHOP cycles followed by six cycles of a more intensive protocol in prognosticall…

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.

BMC cancer · 2024 · PMID 38267866

HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles. The primary efficacy endpoint was overall survival (OS), and se…

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Hepatology communications · 2025 · PMID 41335575

BACKGROUND AND AIMS: Immunosuppression can cause hepatitis B virus (HBV) reactivation, leading to severe outcomes in patients with "resolved" HBV infection. This multicenter, randomized, placebo-controlled trial assessed the efficacy of preemptive antiviral therapy in HBsAg-negative, anti-HBc-positive patients receiving rituximab-based chemotherapy for non-Hodgkin lymphoma (NHL). METHODS: Patients were randomized 1:1 to tenofovir alafenamide (TAF)/placebo across 3 phases: chemotherapy plus TAF/placebo (phase 1), TA…

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Blood advances · 2025 · PMID 40829107

In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed i…

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology · 2026 · PMID 41746629

IMPORTANCE: Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. OBJECTIVE: To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)-based regimens. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, intergroup study was c…

R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.

British journal of haematology · 2024 · PMID 37996986

Anti-CD20 antibody in combination with chemotherapy extends overall survival (OS) in untreated advanced-stage follicular lymphoma (FL), yet the optimal associated therapy is unclear. Data on the cumulative incidence of secondary malignancies postrelapse after conventional immunochemotherapy are scarce. A long-term analysis of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as first-line treatment was conducted in a randomised clinical trial. A six-cycle R-CHOP regimen was …

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Blood · 2025 · PMID 40499012

Patients with follicular lymphoma who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response and circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at end of induction (EOI) may allow their early identification. A representative cohort of 141 patients from the RELEVANCE phase 3 trial with both available serum samples for ctDNA testing and PET images at randomization and at EOI (week 24) was investigated. Twelve per…

Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.

Current medical research and opinion · 2024 · PMID 39376156

OBJECTIVE: We report patient-reported outcomes (PROs) measuring health-related quality of life (HRQoL) from the ROSEWOOD trial (NCT03332017), which demonstrated superior efficacy and a manageable safety profile with zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) in patients with heavily pretreated relapsed/refractory follicular lymphoma (R/R FL). METHODS: PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) and E…

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.

Blood advances · 2025 · PMID 40106688

We analyzed metabolic response using interim positron emission tomography scan (iPET) in a subset of patients with follicular lymphoma (FL) enrolled in the randomized FOLL12 trial. Patients with grade 1-3a FL with an iPET performed between cycles 4 and 5 of first-line immunochemotherapy (ICT) were included; PET scan had to be centrally reviewed for the definition of Deauville score (DS) and were considered positive for DS 4-5. Overall 123 patients out of 211 with iPET were available for central review. Of these, 43…

Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.

Cancer communications (London, England) · 2023 · PMID 37403255

BACKGROUND: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) but whether the same efficacy can be achieved with reduced chemotherapy regimen of four cycles for non-bulky DLBCL patients with an IPI of 1 remains unclear. This study compared four cycles versus six cycles of chemotherapy in non-bulky low-risk DLBCL patients with ne…

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

EBioMedicine · 2024 · PMID 39631145

BACKGROUND: We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. METHODS: Patients with ESFL were randomised to involved field radiotherapy (IFRT) or IFRT plus 6-cycles cyclophosphamide/vincristine/prednisolone (IFRT + CVP). From 2006 rituximab was added to IFRT + CVP (IFRT + R-CVP). Clinical and multi-omic parameters were evaluated. Findings were validated in two indep…

Endoscopic ultrasound (EUS) elastography-guided fine-needle aspiration cytology (FNAC) versus conventional EUS FNAC for solid pancreatic lesions: A pilot randomized trial.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025 · PMID 39230660

BACKGROUND: Endoscopic ultrasound guided fine-needle aspiration (EUS FNA) is the first-line modality to diagnose suspected solid pancreatic malignant lesions. Elastography-guided FNA has been shown to improve the diagnostic yield of EUS FNA but prospective studies are limited. The aim of the study was to compare diagnostic accuracy, sensitivity and specificity of conventional and elastography-guided EUS FNA in patients with suspected malignant pancreatic solid masses. METHODS: Patients with suspected malignant soli…

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.

Leukemia · 2024 · PMID 38538861

The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years. The study protocol included RT for patients with bulky (maximum diameter ≥7.5 cm) or extranodal disease. Two-hundred sixty-one patients were analyzed, 120 of whom underwe…

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).

Cancer research and treatment · 2023 · PMID 35381164

PURPOSE: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin's lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial …

Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.

Hematological oncology · 2025 · PMID 41117344

Patients with Hodgkin lymphoma (HL) or peripheral T-cell lymphoma (PTCL) who relapse after high-dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab-vedotin (BV) is a CD30-targeting antibody-drug-conjugate (ADC) used in first-line-, salvage-, and maintenance-therapy of HL, as well as first-line- and salvage-therapy of PTCL. In phase I of this trial, we could show that BV can safely be added to BeEAM-HDCT (bendamustine, etoposide, cytarabine and melphalan). Here, we report the randomized phase II part of th…

The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · PMID 37014666

PURPOSE: This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival. EXPERIMENTAL DESIGN: The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60.…

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · PMID 38096461

PURPOSE: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. PATIENTS AND METHODS: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance …

The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.

British journal of haematology · 2025 · PMID 40419413

The UK National Cancer Research Institute (NCRI) phase 2 randomised CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T) trial compared the regimens of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) and gemcitabine, cisplatin and methylprednisolone (GEM-P) in treatment-naïve patients with peripheral T-cell lymphoma (PTCL). Evaluation of the role of positron emission tomography/computed tomography (PET/CT) was a key secondary end-point. All patients require…

Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial.

Scientific reports · 2024 · PMID 39043871

In the frontline high-dose phase 3 FIL-MCL0208 trial (NCT02354313), 8% of enrolled mantle cell lymphoma (MCL) patients could not be randomised to receive lenalidomide (LEN) maintenance vs observation after autologous stem cell transplantation (ASCT) due to inadequate hematological recovery and 52% of those who started LEN, needed a dose reduction due to toxicity. We therefore focused on the role played by CD34 + hematopoietic stem cells (PBSC) harvesting and reinfusion on toxicity and outcome. Overall, 90% (n = 245…

End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

European journal of nuclear medicine and molecular imaging · 2024 · PMID 38795120

PURPOSE: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. METHODS: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy f…

A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma.

Indian journal of cancer · 2023 · PMID 38185869

INTRODUCTION: Bendamustine-rituximab (BR) is the preferred regimen for the treatment of naïve follicular lymphoma (FL). Recently, lenalidomide-rituximab (LR), a chemotherapy-free protocol, has shown a good response rate in advanced FL. These regimens have never been compared in a randomized controlled trial for treatment-naïve FL in Indian patients. MATERIALS AND METHODS: This Phase III open-label randomized controlled trial was conducted to compare the efficacy and safety of BR and LR. Treatment-naïve patients old…

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.

Leukemia · 2026 · PMID 41145670

The firstMIND trial (NCT04134936) evaluated the safety and efficacy of adding lenalidomide to R-CHOP+tafasitamab in the first-line treatment settings of patients with diffuse large B-cell lymphoma. To address response dynamics and the impact of measurable residual disease (MRD), we analyzed prospectively collected plasma samples from 56 study patients using the EuroClonality immunoglobulin gene (IG)-NGS assay. At baseline, disease-related clonotypes were identified in 50/56 (89%) patients by IG-NGS in cell-free (cf…

Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Clinical and translational science · 2025 · PMID 40009571

E7777 is a therapeutic recombinant fusion protein comprised of diphtheria toxin fragments and human interleukin-2 (IL-2). Treatment with E7777 generates anti-drug antibodies (ADA). E7777-G000-302 assessed the efficacy and safety of E7777 in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Here, we describe the association between E7777 (at 9 μg/kg) and ADAs, and its effect on pharmacokinetics (PK), efficacy, and safety. Of 91 patients with immunogenicity results at baseline, 78.0% and 5.5% had…

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.

Cancer biology & medicine · 2025 · PMID 40072044

OBJECTIVE: Our previous studies have indicated potentially higher proliferative activity of tumor cells in Chinese patients with mantle-cell lymphoma (MCL) than those in Western. Given the success and tolerability of R-DA-EDOCH immunochemotherapy in treating aggressive B-cell lymphomas, we designed a prospective, phase 3 trial to explore the efficacy and safety of alternating R-DA-EDOCH/R-DHAP induction therapy for young patients with newly diagnosed MCL. The primary endpoint was the complete remission rate (CRR) a…